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I.

INTRODUCTION AND REVIEW OF THE LITERATURE

PURPOSE:
The studies incorporated in this dissertation are designed
to add to, using neurochemical techniques, the pharmacological
evidence that cholinoceptive neurons in the central nervous
system, under certain conditions, have the ability to modulate
central adrenergic neurons, reflected as a change in the levels
of norepinephrine and/or dopamine.

A.

CHOLINOCEPTIVE PATHWAYS OF THE BRAIN:
The mapping of cholinoceptive neuron$ in the central nervous

system has till now met with considerable difficulty.

Lack

of specific histochemical or of the more recently developed,
fluorescent microscopy techniques, has made direct identification
of cholinoceptive neurons impossible and therefore evidence
obtained thus far has been indirect.
The presence of acetylcholine, choline acetylase, and

'

acetylcholinesterase has been used to locate cholinoceptive
neurons (Hebb, 1963 and Koelle, 1963).

In addition, Feldberg

(1957) and Machne (1963) conducted experiments with both
systemically and topically applied cholinomimetics, cholinesterase
inhibitors, and cholinergic blocking agents.

Stimulation and

p

2

blocking of recorded responses was thought to indicate presence
of cholinoceptive neurons.

Another approach to the identifi-

cation of central cholinoceptive neurons was to identify
acetylcholine in the subcellular synaptic fraction from brain
tissue.

Whittaker (1963), DeRobertis(l963), Ryal! (1963),

and Curtis (1964), were among the first to conduct such experiments.

Their findings demonstrated that acetylcholine was

present in the subcellular fraction containing the synaptic
vesicles·.

Although this type of evidence added support to the

concept of the role of acetylcholine as a central neurotransmitter,
it did not however, define specific cholinoceptive pathways.
Probably the most direct evidence of cholinoceptive pathways
comes from studies using microelectrophoretic application of
acetyicholine and cholinomimetic agents directly on central
neurons while recording extra- or intracellularly.

Single

neurons responding to injected acetylcholine are considered to
be cholinoceptive.

Central mapping of cholinoceptive neurons

has been done primarily in cat, however, neural and other
physiological variances may exist between cat and rabbit.

As

these two species are similar in levels of transmitters found
within specific brain areas, the nerve tracts in these two
species could be considered as, also similar.
Curtis and Eccles (1958), Curtis et al.

Evidence by

(1961), and Curtis

(1965) demonstrated cholinoceptive nerve paths in the spinal
cord of cat.

Bradley and Wolstencroft (1962 and 1965) added

evidence of cholinoceptive neurons in the midbrain of cat.
Curtis and Andersen (1961), Curtis and Davis (1963), and

p
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Phillis et al.

(1968) demonstrated cholinoceptive neurons in

cat thalamus.

Margules and Stein (1967) reported the presence

of cholinoceptive synapses in the medial hypothalamic area
in cat.

Curtis et al.

(1963) and McLennan (1964) demonstrated

the presence of cholinoceptive neurons innervating caudate
nucleus in cat.

Curtis and Crawford (1969) reported the

presence of cholinoceptive neurons in spinal cord, thalamus,
hypothalamus, basal ganglia, cerebellum, and in cortex.
Extensiv~

work has also been done on cortical acetylcholine

content.

Krnjevic and Phillis (1963) and Spehlmann (1963)

demonstrated cholinoceptive nerve tracts in cat cerebral cortex.
Other central areas where cholinoceptive neurons have been
located include:

the inferior colliculus (Curtis and Koizumi,

1961); both the mesencephalic and medullary reticular formations
(Bradley and Wolstencroft, 1962; Salmoiraghi and Steiner, 1963};
and the well-documented work of Eccles et al.
et al.

(1954) and Eccles

(1956) demonstrating cholinergic innervation of the

Renshaw cell, which is associated with the spinal motoneurons.
These studies, although far from providing a complete account
of the cholinoceptive nerve tracts in the brain, do clearly
demonstrate that cholinoceptive neurons are widely distributed
from the spinal cord,

rostrall~,

through the medulla, midbrain

thalamus, cortex, and caudate nucleus; in addition to lesser
structures like the inferior colliculus.

Whether these are

long nerve tracts passing through many areas before terminating

I
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on a specific group of cells or short nerve tracts widely
branching through one particular area is not known.

The data

does show, however, that within each of these areas there are
nerves the postsynaptic membranes of which are sensitive to
acetylcholine.

Denisenko (1965) has further clarified the

properties of these cholinoceptive membranes.

He has demon-

strated that certain areas of the brain have nicotine

~

sensitive

cholinoceptive neurons, i.e. cortex, while some areas are
more muscarine sensitive, i.e. midbrain.

More recently,

Krnjevic (1969) has reported that many more sites in the
cortex, brainstem, and at other subcortical levels, in the
cerebellum and in the medulla respond to acetylcholine
muscarinically rather than nicotinically.

Anden et al.

(1966)

in their studies on the effects of induced blockades and
facilitations of dopamine transmission, found asymmetrical
syndromes evoked from the intact corpus striatum.

Previous

evidence of Macintosh (1941), Feldberg and Vogt (1948), and
Burn and Chipman (1951) had shown that the neostriatum contained high concentrations of acetylcholine, choline acetylase,
and acetylcholinesterase.

In addition, Koelle (1954) indicated

that neostriatal nerves, containing acetylcholinesterase,
represented true acetylcholine,nerve terminals within this
structure.

These cholinoceptive nerves ascend uncrossed in

the crus cerebri and in the internal capsule.

Shute and Lewis

(1963) found that there was a severe loss of ipsilateral

5

acetylcholinesterase activity in the neostriatum after unilateral
lesions at the junction between the mesencephalon and the
diencephalon.

From these results, Anden et al.

(1966) con-

cluded that in their lesion experiments, neostriatal acetylcholine terminals were also removed; and they, in fact, had
found a reduction of acetylcholinesterase activity in the
ipsilateral neostriatum much as Shute and Lewis had.

It was

their conclusion that cholinoceptive neurons to the neostriatum
are functional antagonists of the neostriatal dopamine neurons.
Schematic diagrams of central cholinoceptive pathways have
frequently been published.

Stein (1970) has proposed a

cholinoceptive pathway to explain his results on the pharmacology of the reward and punishment systems.

It was found

that application of the cholinomimetic agents, carbachol
and physostigmine, to the medial hypothalamic area restored
the inhibitory effect of punishment; and usually depressed
the rate of unpunished behavior, as well.

Stein concluded that

the punishment system has a critical focus in the medial
hypothalamus and that cholinoceptive synapses are formed at
this level.
At best we can state that the telencephalon and midbraindiencephalon areas do contain the enzymatic systems for synthesis
of acetylcholine, as well as, 'its degradation.

Also contained

within these areas are cholinoceptive sites which can be
stimulated by acetylcholine and other cholinomimetic agents;
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and can be blocked b¥ various cholinolytic drugs.

It is

evident that cholinoceptive neurons have wide distribution

in the mammalian brain.

Specific nerve tracts within the

individual areas, as well as, their role in neuromodulation

is at present still vague.

B.

CATECHOLAMINE PATHWAYS IN THE BRAIN:
Unlike the case with the cholinergic system, recent tech-

nology has allowed ·for accurate mapping of the adrenergic
nerve tracts in the central nervous system, using the fluorescence microscopy techniques developed by the Swedish group.
'Illese techniques not only localize,adrenergic nerve paths,
but also differentiate quantitatively between norepinephrine
and dopamine containing neurons.

Using histological sectioning,

individual nerve tracts can be traced from origin to termination.
~owever,

in intact and untreated animals, it is not possible

to demonstrate the parts of the neuron connecting the nerve
cell body and the terminal portions.
al.

It was found by Anden et

(1966) that by either using a monoamine oxidase inhibitor

or by making a lesion in the various monoamine neuron systems,
they were able to demonstrate and map out many of the ascending
monoamine neuron tracts.

These adrenergic tracts have so far

"

only been demonstrated in the rat.

One would assume with some

variations that rabbit nerve tracts would closely parallel those
found in the rat.

7

nerve tracts:
-oopamine
Dopamine nerve cell bodies originating

in the substantia

nigra area of the mesencephalon project rostrally and become
aggregated in a bundle which ascends just medial and dorsalmedial to the ventral part of the crus cerebri.

.At the level

of the posterior part of the median eminence the bundle
turns into the ventral rostral part of the crus cerebri and
enters and diverges into the retrolenticular part of the
internal capsule.

Running rostrally and dorsally in the

internal capsule the nerves then ascend in the fibrae capsulae
internae to innervate the neostriatum (caudate nucleus and
putamen).

It has been found that the neostriatum contains

close to 80 percent of the brain dopamine, which is correlated
with the large nerve bundle innervating this region.
An additional large dopamine nerve tract was also found.
Cell bodies for these nerves arise in the median/mesencephalon
region and ascend medially to the crus cerebri into the medial
forebrain bundle innervating the tuberculum olfactorium and
the nucleus .accumbens.

These nerve bundles run lateral to

the norepinephrine nerve tracts, also running rostrally,
and

vent~omedially

tQ those dopamine nerve fibers which

innervate the neostriatum.

'

Dopamine neurons have also been shown to innervate the
retina of the eye, with both the cell bodies and terminals
l'.ocated there.

8

N,_orepinep~rine

nerve tracts:

Initial studies by Dahlstrom et al.

(1962), followed by

the investigations of Dahlstrom and Fuxe (1964 and 1965),
Anden et al.

(1966), and Anden et al.

(1965) have demonstrated

the location of norepinephrine nerve tracts in the central
nervous system.

Using lesion-histochemical techniques, it

was found that at least 75 percent of the ascending norepinephrine
neurons originate in cell bodies of the pons and medulla
oblongata.

These fibers innervate various nuclei of the

hypothalamus including the nucleus dorsomedialis hypothalamic,
the nucleus paraventricularis, and the nucleus periventricularis
hypothalamic.

These neurons, in addition, innervate the

thalamus, the preoptic area, the ventral part of the nucleus
interstitialis striae terminalis, the septal area, the
arnygdaloid complex, the hippocampal formation,
cinguli, and the pyriform and neocortex.

the gyrus

Fibers to the neo-

cortex ascend from the medial forebrain bundle dorsally into
the tractus diagonalis and then turn caudally into the superficial parts of the white substance.

Cell bodies of these

neurons were found in the pons and the nucleus reticularis
lateralis of the medulla oblongata.

Carlsson et al.

(1964)

had shown that bulbo-spinal norepinephrine neurons also arise
from these cell bodies.

'

An additional 25 percent of the norepinephrine neurons
innervating the telencephalon have their cell bodies in the
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formatio reticularis of the mesencephalon.

Norepinephrine

cell bodies have not as yet been found in the neocortex itself,
although norepinephrine neurons richly innervate this structure.
Apart from the identification of the specific dopamine
and norepinephrine nerve tracts coursing through the brain,
nerve terminals containing either norepinephrine and/or
dopamine have been found in large numbers within all areas
of the central nervous system.

The density of nerve terminals,

based on the relative intensity of the histochemically
developed fluorescence, related directly to the levels of
norepinephrine and/or dopamine in these structures.
In conclusion, adrenergic neurons, referring specifically
to those containing norepinephrine and dopamine, maintain
their cell bodies in the mesencephalic portion of the brain
and send their nerve fibers rostrally and caudally innervating
the spinal cord, diencephalon, telencephalon, and neostriatum.
Although these studies indicate the major nerve bundles
contained in the adrenergic system, minor complexities
associated with these pathways, as well as, the exact neuromodulating role of the neurotransmitters, norepinephrine and
dopamine, are not yet well defined.

Present evidence indicate

that norepinephrine has. an excitatory effect upon central

"

neurons (Salmoiraghi, 1966) with influence upon
functions,

11

vegetative 11

i.e. temperature control, neuroendocrine regulation

Of pituitary function, control of mood, as well as,

"non-

10

vegetative" functions,
activity.

i.e. control of posture and motor

In the case of dopamine, however, the effect

upon central neurons, primarily in the basal ganglia,

is

that of inhibition (Wurtman, 1966 and Salmoiraghi, 1966),
which is postulated to be antagonistic to the excitatory
actions of acetylcholine in this region (Anden et al., 1966).

c.

EVIDENCE OF CHOLINERGIC-ADRENERGIC COUPLING:

PERIPHERAL

AND CENTRAL

Peripheral:
classification of the postganglionic nerve fibers of the
entire autonomic nervous system was performed by Dale in 1934.
He defined autonomic transmission as being either

11

adrenergic 11

or "cholinergic" based on the neurohumor involved in the
transmission of impulses from the nerve endings to the effector
organ.

Otto Loewi, in 1921, had already postulated the role

of acetylcholine in parasympathetic transmission; and Von
Eular, in 1931, had implicated noradrenaline in sympathetic
transmission.

Thus Dale's classification was not speculative;

the results of these earlier studies provided supportative
evidence for his classificatiop.
The concept of the cholinergic-adrenergic link was advanced
in 1958 by Burn and Rand, although first mention of mixed

J
~-
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·cbolinergic and adrenergic postganglionic sympathetic fibers
,,as made by Dale in his 1934 publication.

Dale defined post-

qanglionic parasympathetic fibers as "cholinergic" and added
tbat, "postganglionic sympathetic fibers are predominantly
.tbough not entirely 'adrenergic'".

-

Dale's inclusion of

cbolinergic fibers within the postganglionic sympathetic supply

was later confirmed in part by the demonstration of cholinergic
fibers in the postganglionic supply to the nictitating membrane
of the cat (Bacq and Fredericq, 1935); to the dog uterus
(Sherif, 1935); and from the stellate ganglion of the heart
(Folkow et al., 1948).

Koelle in 1955 demonstrated the presence

of choline acetylase and cholinesterase in adrenergic neurons,
both of which are involved in synthesis and degradation of
acetylcholine.

Thus, considerable evidence had accumulated

prior to the hypothesis of Burn and Rand which strongly suggested
that a cholinergic-adrenergic link existed.

It was, however,

the hypothesis put forth by Burn and Rand in 1958 which advanced
the role of acetylcholine in the release of adrenergic neurotransmitters at the postganglionic sympathetic nerve endings.
Their postulation was that, "all the postganglionic sympathetic fibers

•

have cholinergic mechanisms involved in the release of
noradrenaline after nerve stimulation, i.e. postganglionic
sympathetic nerve stimulation first releases acetylcholine
Which triggers off the mechanism by which noradrenaline is
liberated from the local tissue stores at the sympathetic

12

l'

postganglionic nerve endings".

Jaju, in 1969, discussed three

· passible neural mechanisms which would explain the Burn and
Rand hypothesis.

First, that postganglionic fibers might

release only acetylcholine which would in turn release
noradrenaline from the adjacent chromaffin cells, a mechanism
similar to that operating in the adrenal medulla.

Secondly,

the release of acetylcholine by the postganglionic impulse
might initiate or facilitate the liberation of noradrenaline
from different nerve fibers.

Thirdly, the release of acetyl-

choline from the postganglionic fibers might initiate or
facilitate the liberation of noradrenaline from the same
fiber.

The second explaination seem most reasonable based

on previous evidence of mixed cholinergic and adrenergic
fibers in the postganglionic supply.

Whether or not the

Burn and Rand concept of cholinergic-adrenergic coupling
will finally be accepted or rejected is still a mute question.
What seems evident, is that cholinergic-adrenergic coupling
does exist (cf. Karczmar, 1967).
One of the earliest observations of cholinergic-adrenergic
linkage was reported by Brucke in 1935.

It was observed that

a small dose (Spg) of acetylcholine injected at the base of a
tuft of hairs in cat's tail pI."t>duced piloerection which was
similar in response to that seen after sympathetic stimulation.
Coon and Rothman, in 1940, observed results similar to those
observed by Brucke, using acetylcholine and nicotine.

Burn

13

et al.

(1959) were able to demonstrate that reserpinization

abolished the piloerection response to both nicotine and to
a small dose of acetylcholine, reserpine having caused a
marked decrease in the amount of norepiniphrine, as well as
the number of chromaffin cells and their granules in the
skin of the cat's tail.

Further support of the role of

acetylcholine in sympathetic stimulation came from Burn and
Rand's observations (1962) that hemicholinium, known to block
the synthesis of acetylcholine, when injected into the base of
the tufts of hairs caused a slower erection of the tufts
of hairs to repeated sympathetic stimulation.
tufts of hairs were still erect.

The

autho~s

Untreated
concluded that

nicotine and small doses of acetylcholine liberated norepinephrine
which produced the piloerection.

This response was greatly

reduced after blockade of acetylcholine synthesis by hemicholinium and absent after depletion of catecholamine stores
by reserpine or nerve degeneration.

More recently, Rand and

Whaler (1965) have shown that botulinum toxin, which blocks
release of acetylcholine from cholinergic neurons, prevents
piloerection when injected into the base of tufts of hairs in
cat's tail.

The authors concluded that acetylcholine release

was essential for piloerection,following sympathetic nerve
stimulation.
Studies on the nictitating membrane have added evidence
of

a

cholinergic-adrenergic link.

Bacq and Fredericq (1935}

....--,.
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'

first demonstrated cholinergic fibers innervating the nictitating
membrane of the cat.

Burn and Rand (1960) found that in

reserpinized cats, contraction of the nictitating membrane

by stimulation of postganglionic sympathetic fibers was
potentiated by eserine and blocked by atropine, suggesting
release of an acetylcholine-like substance by sympathetic
fibers.

Burn et al.

(1963) expanded on these findings using

isolated nictitating membrane preparations.

'

Further, Ambache

(1951) using botulinum toxin, which blocks the release of
acetylcholine from cholinergic neurons, observed greatly
reduced contractions of the nictitating membrane to sympathetic
stimulation.

J'acobowitz et al.

(1965) using neuronally

induced contractions of the nictitating membrane in rabbits
observed that hemicholinium, which inhibits synthesis of
acetylcholine, produced a reversible reduction in isometric
contractions of the nictitating membrane to supramaximal
tetanic stimulation of the sympathetic postganglionic trunk.
Similarly, Burn et al.

(1963)using hyoscine demonstrated a

hyoscine resistant component of nictitating membrane contractions
stimulated postganglionically supramaximally at high frequencies.
They concluded that the hyoscine resistant component was
adrenergic in nature, while tbf? hyoscine sensitive component
was cholinergic.

Burn et al.

(1963) observed that in

nictitating membrane of cat treated with hyoscine or atropine,
contractions to acetylcholine which should have been blocked

15

were in fact potentiated with neostigrnine far more at supramaximal postganglionic stimulation frequencies below 5/second,
than above.

.

These studies on nictitating membrane indicate that acetylcholine is involved to some extent in the modification of
responses to sympathetic stimulation, although the mechanisms
involved are unclear from these results.
Involvement of acetylcholine in response to sympathetic
stimulation have also been observed on intestine and colon.
Gillespie and Mackenna (1959 and 1961) observed that in
reserpinized animals electrical stimulation of the sympathetic
neurons produced contraction of the colon.

It was further

demonstrated that this effect could be blocked by atropine.
Burn and Rand (1962) continued these studies demonstrating
that hemicholinium reduced the inhibitory effects of sympathetic
stimulation on the isolated colon of untreated animals.

In

addition, they were able to demonstrate reversal of this effect
with the addition of choline. It was concluded by the authors
that the reduced adrenergic response was due to the reduction
in acetylcholine by hemicholinium.

Similarly, Rand and Whaler

(1965) found that botulinum toxin blocked the inhibitory
effect of nerve stimulation in isolated rabbit ileum.
et al.

Burn

'

(1963) found a biphasic response to low and high

frequency stimulation on the isolated rabbit ileum with
mesentary attached.

Their results suggested that at lower

16

frequency both acetylcholine and norepinephrine were released,
while at the higher frequencies only norepinephrine was released.
Their conclusions were based on evidence that hyoscine increased
the inhibitory effect of nerve stimulation on the ileum at
low frequencies, but was ineffective at the higher frequencies.
studies by Sjostrand (1961) on the isolated vas deferens
of guinea pig, which were previously thought to contain only
sympathetic innervation, have shown that acetylcholine
potentiates the response of the vas deferens to electrical
stimulation.

Boyd et al.

(1960), Burn and weetman (1963),

Ohlin and Stromblad (1963), and Riley and Maanen (1962) found
potentiation of the isolated vas deferens response to electrical
stimulation using physostigmine and neostigmine.

Chang and

Rand (1960) demonstrated decreased responses of this preparation to nerve stimulation using hemicholinium.

Rand and

Whaler (1965) have additionally shown that botulinum toxin
abolished the contractions of the vas deferens to sympathetic
nerve stimulation.

These studies suggest a role of acetylcholine

in the sympathetic response of the vas deferens to nerve
stimulation.
Cholinoceptive neurons were reported (Sherif, 1935) to be
contained in the sympathetic

~upply

to the uterus in dog.

Later, Burn and Rand (1960) reported that in reserpinized cats,
stimulation of the hypogastric nerve produced contraction of
the uterus contrasting the inhibitory effect normally observed.

,,..--··
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'I'h.is stimulant effect, seen in reserpinized cats, was potentiated
by eserine and blocked by atropine.

It was concluded from

the observations that acetylcholine was involved in the
excitatory effect on uterus following postganglionic nerve
stimulation in reserpinized cats.
Numerous investigators:
al.

(1939), Holtz et al.

Ahlquist et al.

(1954), Grindly et

(1952), and Ottis et al.

(1957) have

demonstrated the ability of epinephrine to contract the spleen.
Burn and. Rand (1962) found that after stimulation of the postganglionic nerves to the spleen, the volume of the spleen
either increased or decreased in reserpinized animals.

In

those cases where an increase in volume was observed, it
was found that eserine would potentiate the response while
atropine blocked the dilatation of the spleen.

In those

cases where contraction of the spleen was observed, indicated
by the decrease in volume, eserine was without effect.

Atropine

did have an effect, converting the increase into decrease in
volume of the spleen.

The authors suggested the latter

response to atropine resulted from incomplete depletion of
catecholamines by reserpine and subsequent release following
nerve stimulation producing the observed contraction.

Further,

Bradon and Rand (1961) demonstfated the release of acetycholinelike substance following postganglionic nerve stimulation in
reserpinized cats.

Using perfusate collected after nerve

stimulation they observed that this perfusate would cause
,
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the isolated guinea pig ileum to contract and atropine was
found to block the contraction produced by the perfusate.
Application of neostigmine to the reserpinized cats caused
an increase in the amount of acetylcholine-like substance
released upon nerve stimulation.
Other investigators:

Farber (1936), Daly et al.

(1961),

Bradon and Boyd (1961), and Bradon and Rand (1961) have also
observed sympathomimetic effects of acetylcholine upon the
spleen in both dog and cat.

They found that upon close intra-

arterial injection of acetylcholine into the spleen, contraction
of the spleen occurred.

Reserpinization, dibenzyline or hexa-

rnethonium pretreatment, or nerve degeneration of the sympathetic
supply were found to block this response.

Ferry (1963) has

further shown that acetylcholine in the presence of atropine
causes contraction of the spleen.
by bretylium and hexamethonium.

This effect could be blocked
A direct excitation of post-

ganglionic adrenergic neurons was therefore suggested for the·
action of acetylcholine.

Bretylium's blocking action, it was

suggested, was upon the release of catecholamines by acetylcholine while hexamethonium's •locking action prevented the
entry of acetylcholine into the sympathetic neuron (Burn and
Gibbons, 1964).

More recently, Krauss et al.

(1970) have

shown that intra-arterial injection of acetylcholine evoked
release of norepinephrine from the isolated perfused cat spleen
and induced antidromic nerve impulses in the splenic nerve.

r
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~
:. Tetrodotoxin, it was shown, prevents release of norepinephrine
by splenic nerve stimulation and blocked the antidromic

discharges, however, it did not block the release of norepinephrine
by acetylcholine.

Further, it was shown that a single dose

of bretylium blocked the release of norepinephrine to splenic
_nerve stimulation but not release due to acetylcholine.
Higher concentrations of bretylium were able to block the
release of norepinephrine by acetylcholine in the tetrodotoxin
treated spleen.

Hemicholinium was shown by Bradon and Rand

(1961) to block contraction of the spleen produced by stimulation
of the sympathetic neurons; the addition of choline reverses
the hemicholinium block.

These studies suggest that after

depletion of acetylcholine, nervous stimulation is ineffective
in producing the sympathetic response in spleen.

In the rat

spleen, electron microscopic studies have revealed two types
of vesicles within the terminations of sympathetic neurons;
one containing dense granules and the other type which was
not granular but homogeneous (De Robertis and Pellegrino de
Iraldi, 1961).

Following reserpine pretreatment, the granular

vesicles disappeared.

It has been
shown by autoradiography
'

combined with electron microscopy that the granular vesicles
store 3H-norepinephrine within the terminals of the sympathetic
nerves supplying the rat spleen.
Studies on cardiac tissues also favor the cholinergicadrenergic concept.

Hoffman et al.

(1945) studies the effects

20
of acetylcholine upon isolated perfused and atropinized
hearts from cat, rabbit, and guinea pig.

He observed positive

inotropic and chronotropic effects produced by acetylcholine
which closely resembled those effects observed following
sympathetic stimulation.

Such evidence suggested release of

catecholamine-like substances by acetylcholine to produce
the effects.

Their suggestion was confirmed when an epin-

ephrine-like substance was identified in the perfusate.

In

addition, sympathetic denervation of the heart and reserpinization either reduced or blocked the effect of acetylcholine
(Cabera et al., 1966).

Moreover, Hukovic (1960) demonstrated

that both 2:6 xylyl ether and bretylium, both of which block
release of catecholamines, blocked the acetylcholine induced
positive inotropic effect on isolated atria in the presence
of atropine.

Similarly, nicotine has been reported to produce

a biphasic response on isolated heart and atria of cat,
rabbit, and guinea pig (Giotti, 1954; Kottegoda, 1935; Leaders
and tong, 1962; McDowall, 1946; and Trendelenburg, 1960).
Chiang and Leaders (1965) demonstrated a similar biphasic
effect of nicotine on isolated rat atria.

'

Kottegoda (1953)

reported that in atropinized perfused rabbit atria, nicotine
increased both the force and rate of atrial contraction and
that hexamethonium, a ganglionic blocking agent, blocked
these effects to ganglion stimulatory properties of nicotine;
however, Lee and Shideman, in 1959, found similar responses
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of nicotine on cat papillary muscles devoid of ganglia.
Kottegoda's responses to nicotine, it appeared, were not
due to ganglionic stimulation.

Burn and Rand (1958) reported

that reserpinization or denervation of the rabbit atria,
depleting the nerve endings of catecholamines, decreased or
abolished any stimulatory effects of nicotine on the atria.
These studies suggest that like acetylcholine, nicotine is
involved in catecholamine mediated responses of the atria.
studies on the isolated rabbit atria following stimulation of
sympathetic neurons innervating the atria have shown that
in normal rabbits a positive chronotropic response was produced.
However, in reserpinized rabbits a negative inotropic response
was observed.

In addition, eserine potentiated and atropine

blocked this inhibitory effect (Burn and Rand, 1962).

Similar

studies by Day and Rand (1961) showed that after guanethidine,
stimulation of postganglionic neurons of cat atria caused
a cardio-inhibitory effect.

Using the same preparation,

Leaders, in 1963, found in normal cats that stimulation of
the sympathetic fibers produced a classical cardio-stimulant
effect followed by a small consistent cardio-inhibitory effect

'

and this inhibitory effect could be potentiated by eserine
and blocked by atropine.

In addition, hemicholinium was

able to block the inhibitory response in both normal and
reserpinized atria suggesting that acetylcholine is directly
involved in atrial responses seen after stimulation of
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sympathetic nerve fibers.
Evidence of cholinergic involvement in responses of
blood vessels to sympathetic stimulation has been demonstrated
by Burn and Dutta (1948) and by Kottegoda (1953).

They

reported that in the presence of atropine, both acetylcholine
and nicotine produced vasoconstriction in rabbit's ear
vessels.

Moreover, tolazoline, an alpha adrenergic blocking

agent, reversed the vasoconstriction response of acetylcholine
and nicotine.

From the results, it was concluded that acetyl-

choline released catecholamines from the sympathetic terminals
which stimulated the beta receptors causing the vasodilatation.
Burn and Rand in 1958 reported in addition, that in the
presence of atropine, acetylcholine and nicotine failed to
produce vasoconstriction of the rabbit ear vessels following
reserpinization or denervation.

Hukovic (1960) further

demonstrated that 2:6 xylyl ether and bretylium both blocked
the vasoconstrictor effect suggesting that the vasoconstriction
response to acetylcholine is mediated through norepinephrine.
Stimulation of postganglionic sympathetic neurons supplying
rabbit ear vessels is known to produce vasoconstriction of
the vessels.

'

Horton and Rand (1962) demonstrated that the

vasoconstriction response to postganglionic nerve stimulation
caused a decrease in blood volume followed by vasodilitation.

It

was also shown that eserine potentiates this vasodilatation and that
atropine blocks this response.

Similarly, Burn and Rand (1962)

reported that administration of hemicholinium blocked the vasoconstrictor
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. effect of nerve stimulation on rabbit ear vessels and that
the hernicholinium block

co~ld

be reversed by choline administration.

It was concluded that nerve stimulation released ACh which in
turn released norepinephrine producing the vasoconstriction.

In

support of their conclusions, evidence was presented showing that
perfusate collected from the ear vessels contained a substance
which caused the leech muscle to contract, presumably acetylcholine.
More recently, Rand and Varma (1970) demonstrated that low doses
of acetylcholine, muscarine, and pilocarpine enhanced the vasoconstriction of the rabbit ear artery in

response to sympathetic

I

nerve stimulation, while high doses depressed these effects and
atropine was shown to block this depressant effect.

In

addition, it was reported that acetylcholine and methacholine
enhanced the vasoconstrictor response to injected norepinephrine.
It was suggested from these results that these cholinomimetic
drugs act to facilitate or impair (depending upon dosage) the
release and uptake of norepinephrine from adrenergic terminals
associated with rabbit ear artery.

Loffelholz and Muscholl

(1970) demonstrated, using isolated rabbit atria perfused
with Tyrode solution containing amphetamine, that electrical

"

stimulation of the right postganglionic sympathetic neurons
caused release of norepinephrine which could be markedly
decreased by simultaneous stimulation of vagal nerves.

The

results, it was suggested, indicate an inhibitory cholinergicadrenergic interaction.

24
Using hind limb vessels in dog, Burn in 1932, demonstrated
that stimulation of sympathetic neurons to the hind limb produced
vasoconstriction in some experiments and vasodilatation in
others.

Bulbring and Burn in 1935 showed that some of these

fibers were cholinoceptive in nature.

Burn (1961) and Mccubbin

(1961) using guanethidine, which blocked norepinephrine
release, found that sympathetic nerve stimulation to dog hind
limb produced vasodilatation which could be blocked by atropine.
Bernard and Schaepdryver (1964) were able to demonstrate that
electrical.stimulation of the nerve supply to dog hind limb
produced vasoconstriction that in atropinized dogs was potentiated by anticholinesterases.

Cholinergic involvement in

sympathetic stimulation of dog hind limb vessels seemed
indicated.
Studies using perfused accessory cephalic vein of the dog
(Rice and Long, 1966) demonstrated that acetylcholine injected
into the perfusing fluid produced vasoconstriction of the
vein which could be inhibited by pretreatment with reserpine
or phentolamine and could be potentiated with cocaine. Further#
the venous effluent following acetylchoiine could relax the

'

chick rectal caecum and this effect could be blocked by
pronethanol, an adrenergic beta blocker.

Hexamethonium had

no effect on the vasoconstriction produced by acetylcholine
ruling out a ganglionic mechanism for the response.

In

reserpinized animals, tyramine has been shown by Chandra et al.

r
•~
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(1965), Maxwell et al.

(1959), and Trendelenburg (1961) to

produce a fall in systemic blood pressure.

This depressor

effect is potentiated by eserine and blocked by atropine
suggesting acetylcholine involvement.
From the volume of evidence reviewed, one would be hard
pressed to doubt the existence of a cholinergic-adrenergic
linkage in the Autonomic Nervous System.

One might, and

rightfully so, question under what conditions such a coupling
phenomena functions and for what purpose.

Hopefully future

studies will enlighten us on these points.
Yet, there are counter arguments to acetylcholine's role
in synaptic transmission as proposed by Burn and Rand (Karczmar,
1969), as well as, other concepts involving acetylcholine
in synaptic transmission.

Koelle (1963) suggested a double

step release of acetylcholine from nerve terminals.

Acetyl-

choline released in the course of the first step would then
impinge upon· the presynaptic nerve terminal, this second
step initiating mass liberation of the transmitter.
At one time, Feldberg (1948) suggested that cholinergic
transmission may never embrace two successive relays, and

'

that the cholinergic mechanism is followed by a noncholinergic
step.
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central:
Evidence of cholinergic-adrenergic coupling within the
central nervous system can be considered as sparse compared
to the volume of evidence dealing with the peripheral nervous
system.

It should not be inferred from this that cholinergic-

adrenergic coupling does not exist within the central nervous
system, but rather it attests to the difficulty in obtaining
meaningful data from so complex and inaccesible a system.
Most of the evidence reported has come from recent studies.
Srimal et al.

(1969) demonstrated, using intracerebroventricular

injections of choline in anesthesized dogs, that a biphasic
blood pressure response was

observed~

an initial hypertensive

phase followed by a delayed hypotensive phase.

The initial

hypertensive phase was felt to be due to choline and was
blocked by atropine.

The delayed hypotensive phase resembled

that observed after intracerebroventricular injection of
norepinephrine.
reserpinizatio~

This hypotensive phase was abolished by prior
and blocked by pronethalol and INPEA, both

adrenergic beta receptor blocking agents.
that the

intracerebroventricul~rly

It was concluded

injected choline stimulated

the central release of norepinephrine to cause the hypotensive
phase.
Additional evidence reported by Przuntek and Philippu (1971)
demonstrated that, in vitro, acetylcholine in the presence
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of calcium accelerated the release of norepinephrine from
intact hypothalamic cells.

In a similar preparation, Philippu

and Przuntek (1967) demonstrated that acetylcholine releases
norepinephrine from the subcellular norepinephrine storing
vesicles of the hypothalamus.

Philippu (1970) further

demonstrated that in cat hypothalamus labelled with 14Cnorepinephrine, the radioactive norepinephrine was found
to be taken up by the synaptosomal fraction.

Moreover, during

perfusion of the third ventricle of cat, labelled norepinephrine
was found to be spontaneously released from the hypothalamus
into the perfusing fluid.

Addition of acetylcholine in the

presence of calcium enhanced the release of labelled norepinephrine
as did electrical stimulation of the hypothalamic nuclei.
Van Meter (1969) and Van Meter and Karczmar (1971) studying
central EEG responses in rabbits to anticholinesterase agents
confirmed the finding of Longo and Silvestrini (1957) that
EEG recruitment could be blocked with eserine, and demonstrated
that the pretreatment with reserpine abolished the antirecruitment effects of eserine and that the replenishment
of the norepinephrine levels fellowing DOPA administration
restored blocking action of eserine on EEG recruitment.

In

addition, this eserine block could not be obtained following
depletion of the norepinephrine levels by alpha-methyl-paratyrosine, but with replenishment of the norepinephrine stores
following administration of DOPA and a monoamine oxidase
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inhibitor, eserine was again able to block the EEG recruitment.
similarly, Karczmar and Longo (1969) and Karczmar et al.

(1970)

observed in reserpinized rabbits that eserine produced EEG
and behavorial syndrome characteristics of the paradoxical
sleep phenomena.

Neither eserine nor reserpine alone

produced these effects.

It was concluded that an interplay

between eserine and reserpine existed and such interplay
was necessary for the paradoxical sleep phenomena to occur
in rabbits.
These data, although few in numbers, clearly point to
possible existence of a cholinergic-adrenergic coupling phenomena
within the central nervous system.

Present methodology, i.e.

fluorescence microscopy, microelectrophoretic drug application,
and ion-exchange chromatography, provides more exacting
results allowing for a clearer interpretation of the results.
The lack of sufficiently refined experimental methodology
seems to be a major hindrance of earlier studies.

The concept

of central cholinergic-adrenergic coupling is even more
convincing if one reflects on the diffuse neural network
we presently understand as comrrising the central nervous
system.

Unlike the more well-defined Autonomic nerve network,

the Central network, with its opposing cholinergic and
\

adrenergic systems, could employ such a coupling phenomena
as a neuromodulating mechanism designed to maintain homeostatic

bal~nce

within the central nervous system.
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ACTIONS OF PERTINENT DRUGS:

-

l-phenyl-3-hydrazinobutane

(JB835)

H
I

structure:

c
~

~

c1.
H

~

H
I

c

N-Ntt

I

CH

2

3

l-phenyl-3-hydrazinobutane (identified in the text by the
more common nomenclature - JB835}, one of a series of compounds
synthesized by John Biel, was found to be a potent inhibitor of
monoamine oxidase, the enzyme responsible for degradation of
dopamine and norepinephrine as well as of epinephrine and serotonin.
Spector et al.

(1959) demonstrated in vitro that JB516, also a

monoamine oxidase inhibitor, and JB835 were equally potent
and completely inhibited the activity of monoamine oxidase
-5
at a concentration of 1 X 10
M within 30 minutes.
Studies with JB835 indicated that a single dose (3mg/kg, iv)
produced 95 percent inhibition of monoamine oxidase in rabbit
brain homogenates within 30 minutes, the inhibition lasting
for 48 hours, subsequently, a 75 percent inhibition lasted
for the next 48 hours.

The su~cutaneous route required longer

periods for the peak effect to occur.

Serotonin was observed

to rise by 50 percent within 15 minutes while accumulation
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for one-half turn-over of the brain pool of serotonin is about
15 minutes, while that of norepinephrine is several hours.
The observed rapid rise in brain serotonin following JB835
suggests that it readily penetrates the brain, as does JB516.
similar observations were made by Brodie et al.

(1960).

Although JB516, the hydrazine analogue of amphetamine,
in doses of lOmg/kg,iv, or higher produced immediate
amphetamine-like central excitation and mydriasis, JB835
in doses up to 40mg/kg,iv produced no such effects.
These results demonstrate JB835's ability to inhibit
monoamine oxidase in brain in rabbits and to increase brain
amine levels without producing central excitation typical of
many monoamine oxidase inhibitors, i.e. JB516.

3,4-DL-Dihydroxyphenylalanine

Structure:

HO

(DOPA)
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DOPA is synthesized in vivo within chromaffin cells and
certain neurons by the hydroxylation of tyrosine (Nagatsu et
al., 1964; Wurtman, 1966).

DOPA is not readily abundant in

blood or tissues in vivo (Anton and Sayre, 1964), suggesting
that it is rapidly metabolized probably by decarboxylation.
When injected, however, DOPA is capable of penetrating into
the brain from the blood (Carlsson et al., 1958).
et al.

Wurtman

(1970) injected small doses (2.5 mg/kg) of 14C labelled

DL DOPA intraperitoneally into mice.

It was found that the

level of 14C-catecholamines in the whole carcass reached
a peak within 20 minutes and that o-methylation was the main
catabolic

pa~h

of the labelled DOPA in the periphery.

Almost

all of the 14C label was found with the dopamine fraction,
a much smaller amount with the norepinephrine fraction, and
essentially none incorporated into protein.

Further, it was

found that only 0.01 percent of the injected label was found
in brain 20 minutes following the injection of the labelled
DOPA as 14C DOPA and 14C dopamine, the remainder of the label
recovered in the periphery.

However, Bartholini and Pletscher

(1968) and Persson and Waldeck (1968) demonstrated, using

'
larger doses of DOPA, that norepinephrine
levels as well as
dopamine levels were elevated in the brain of rats and mice.
/

Similar observations were made in rabbits following DOPA
pretreatment by Glisson and Karczmar (1970}.
Behaviorally, DOPA produces central excitation which is

32

increased by previous inhibition of monoamine oxidase (Carlsson
et al., 1960) as well as stimulate the spontaneous motility
{Carlsson et al., 1957).

Diisopropylfluorophosphate

(DFP)

structure:

DFP's mechanism of cholinesterase inhibition is that of
phosphorylating and thereby inactivating "serine enzymes", i.e.
acetylcholinesterase and butrylcholinesterase.

Since acetyl- ·

cholinesterase is found in erythrocytes, at parasympathetically
innervated effector organs (smooth muscle; glands}, at the
skeletal muscle end-plates, at autonomic ganglia, and in the
central nervous system, administration of the lipid soluble
DFP inhibits at these sites the action of acetylcholinesterase,
which is to hydrolyze the neurotransmitter, acetylcholine.
When the cholinesterase activity is reduced by one-half,
symptoms of accumulation of ac"3tylcholine begin to appear, i.e.
salivation, lacrimation, defecation, and urination.

Further

reduction of the cholinesterase activity to below 10 percent
normal activity will eventually result in death, usually
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aue to respiratory failure, caused in part by neuromuscular
paralysis of the intercostal muscles and diaphram, and in
part by central depression (Goldstein et al., 1969).

DFP's

ability to penetrate the central nervous system is due to
its high l·ipid solubility which allows for easy entry into
the brain.

Regarding the inhibition of various cholinesterases,

-7
in low concentrations (10

-8
- 10

) DFP preferentially inhibits

butrylcholinesterase as does physostigmine at low doses.
-6
At high doses (10 ), however, DFP readily inactivates acetylcholinesterase: a dose of 2.5 mg/kg being more than sufficient
for acetylcholinesterase inhibition (Koppanyi and'Karczmar, 1951).
Grieg and Holland (1949) and Greig

and Mayberry (1951) reported

that the permeability of the blood brain barrier of the
central nervous system is increased by cholinesterase inhibitors.
Fuchsine, barbital, and choralose were shown to have increased
entry into the brain following administration of cholinesterase
inhibitors.

Such evidence is relevant since DFP could

alter the blood brain barrier allowing quaternary drugs
entry into the brain.

Care must be taken to assure that

the effects of quaternary

drug~

in the presence of DFP represent

only peripheral responses (Albanus, 1970: Wills, 1970).
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Atropine sulfate (AtSO )
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The mu~carinic blocking action of the tertiary atropinic
agents is highly specific in as much as the nicotinic sites
such as the ganglia and neuromuscular end-plates are not
appreciably blocked, even by doses greater than those necessary
to produce complete blockade of susceptible muscarinic
receptors.

The mechanism of action of the muscarinic blocking

agents, i.e. atropine sulfate, atropine methyl nitrate, etc.,
involves a decrease in the response of normally sensitive
tissues, i.e. peripheral vascular smooth muscle, gastrointestinal and genitourinary ~mooth muscle, constrictor and
ciliary muscles of the eye, as well as, secretions from
glands such as bronchial, salivary, and gastric, to acetylcholine.

The decreased response may be due to impaired

access of acetylcholine to the muscarinic receptors.

The
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block is competitive in type since very large doses of acetylcholine may "break through" and produce a muscarinic effect.
The primary central nervous system effect at moderate doses
is sedation, while at toxic
(Sutherland, 1970).

~oses

excitation predominates

Further studies using dogs (Albanus, 1970)

indicate that atropine (0.5-2.5mg/kg) produced a decrease
in general locomotor activity and ataxia, marked tachycardia,
depressed salivation, marked mydriasis; Albanus was also
able to produce complete inhibition of the normal blood
pressure response to acetylcholine.

Of importance was that

the centrally induced ataxia seen with atropine could also
be observed with atropine methyl nitrate, the quaternary
atropinic, but only using 100 times the dose of atropine.
This is

co~sistent

with the observations that massive doses

of quate;r-nary compounds will eventually "break through" the
blood brain barrier and enter the central nervous system.
Hingtgen and Aprison (1970) reported that high doses
(0.8mg/kg) of

a~ropine

blocked behavorial excitation in rats,

which they had previously shown to be correlated with central
acetylcholine concentrations

(~prison

et al., 1968).

doses of atropine methyl nitrate had no effect.

Comparable

Polak and

Meeuws (1966) demonstrated that atropine caused a release
of acetylcholine from isolated cerebral cortex in rats,
which Hingtgen and Aprison considered was in part responsible
for the block of behavorial excitation observed by them
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following atropine.
In addition to the above effects, atropine is able to offer
some amount of protection from organophosphorus poisoning.
Johnson and Stewart (f970) reported that in rabbits, atropine
(l.2mg/kg,iv) was able to reverse the respiratory arrest
produced by sarin without affecting the changes in nervemuscle function.

Douglass and Matthews (1952) reported that

of atropine's actions on anticholinesterase poisoning, the
most important one was the central effect in protecting
the medullary respiratory center fran the depressant effect
\

of anticholinesterases.
These results indicate that a dose of 2.0mg/kg of atropine
is adequate to produce blockade of peripheral muscarinic
sites, as well as exert blocking actions within the central
nervous system upon the cholinoceptive sites.

Atropine methyl nitrate

H C
2

Structure:
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The actions of atropine methyl nitrate in the periphery
are identical to those described for atropine sulfate,
although ATMN at the same concentration as atropine sulfate
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is more potent in its ability to block peripheral muscarinic
sites than atropine, probably due to atropine's wider central
and peripheral distribution as opposed to only the peripheral
distribution for ATMN (Goldstein et al., 1969).

The quaternary

structure of ATMN excludes it from easy access into the
central nervous system, although entry can occur using
high doses, i.e. 100 times atropine's dose (Albanus, 1970).
Although central protection is of greatest importance
against respiratory failure in organophosphorus poisoning,
Coleman et al.

(1963) have reported some protection against-

organophosphorus poisoning with ATMN alone or with an oxime,
suggesting that the peripheral sites contribute to the
toxicity.
The evidence indicate that a dose of 2.0mg/kg of ATMN is
sufficient for blockade of peripheral muscarinic sites but
this low dose is incapable of entry into the central nervous
system without alteration of the normal entry mechanisms
(Albanus, 1970; Wills, 1970).
Although recent evidence (Van Meter, 1969; Van Meter and
Karczmar, 1970; Philippu, 1970' indicate anticholinesterase
effects upon central norepinephrine levels, the effects of
anticholinesterases upon central dopamine levels are unknown.
With this background of information, the importance of an
investigation into the effects of anticholinesterases on

~
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dopamine, as well as norepinephrine levels seemed indicated.
AS norepinephrine is formed by the hydroxylation of dopamine,

it would be inconsistent to consider that norepinephrine
was affected by anticholinesterases but not dopamine.
The initial purpose, therefore, was to determine whether
the anticholinesterase, diisopropylphosphofluoridate (DFP),
'would produce a demonstrable effect upon the levels of
dopamine/and or norepinephrine in rabbit brain.

Midbrain-

diencephalon and the caudate nucleus were selected, for their
high amine contents, as the areas to be examined.
Following these initial experiments, additional studies
would be carried out to clarify any observed responses.
It would be important to determine whether the effects upon
norepinephrine and dopamine levels due to DFP were dose
dependent.

In addition, the ability of atropinic agents,

both tertiary and quaternary, to block the DFP-induced effects
should be investigated.
Upon completion of these experiments, it would be necessary
to define more precisely the specific brain areas involved.

'

Using localized brain area, i.e. midbrain, thalamus,
hypothalamus, and hippocampus, the information obtained
would indicate whether the responses to DFP, as well as the
sites of atropinic blockade, were localized or widespread.
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Finally, with regard to norepinephrine and dopamine, studies
using intraventricular injections of DFP would provide information
as to the central responses to DFP, which should closely
mimic those responses seen following peripheral blockade by
the quaternary atropinic, AT.MN.
Since the effects upon norepinephrine and dopamine levels
are postulated to be due to the elevated acetylcholine
levels resulting from DFP's inhibition of cholinesterase
activity; the inhibition of cholinesterase activity and the
resulting elevation of acetylcholine levels should be demonstrated.

Therefore, assay of the percentage inhibition

of the cholinesterase activity produced by DFP, as well
as bioassay of the levels of acetylcholine will be carried
out following the various drug pretreatments.
These experiments will provide pertinent information as
to the neurochemical changes associated with the cholinergicadrenergic coupling phenomena •

•
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II.

MATERIALS AND METHODS

&aterials:
New Zealand albino rabbits were chosen as the biological
material because of their readily availability, their ease
of handling, and the availability of pertinent data obtained
both in this laboratory and elsewhere.

Only male animals were

used in these experiments to avoid possible estrus effects
on the results.

In some of the experiments two brain areas

were used, the midbrain-diencephalon and the caudate nucleus.
The caudate nucleus in rabbit is of sufficient size and
amine content to allow individual determinations.
experiments four individual brain areas were used:

In other
the

thalamus, the hypothalamus, the midbrain, and the hippocampus.
In these latter experiments tissue samples were pooled from
two rabbits to obtain a more accurate determination of the
amine levels in these tissues.
was 2.5 + 0.5 kilograms.

The weight of the rabbits

All animals were housed in individual

rabbit cages located within the animal facilities.
temperature was maintained at

74

degrees Fahrenheit and

food and water was provided to the animals ad lib.

Drugs and dosage:

The room
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l-phenyl-3-hydrazinobutane (JB835) was administered at a
constant dose of 6.0mg/kg whenever used alone or as part
of a drug regime.

The drug was dissolved in physiological

saline and administered via the intraperitoneal route.
3,4-DL Dihydroxyphenylalanine (DOPA) was administered
at a constant dose of SOmg/kg when used either alone or as
part of a drug regime.

The drug, as the hydrochloride, was

heated in physiological saline until dissolved, allowed to
cool, and administered via the intraperitoneal route.

Although

the DL form of this drug was used as it is readily available
in this form it has been demonstrated that only the L form
is capable of conversion to dopamine by DOPA decarboxylase
(Cooper et al., 1970).

The functional dosage would there-

fore be 25mg/kg.
Diisopropylfluorophosphate (DFP) was administered in three
different dosages in the various experiments.

Although in

one experimental series l.Omg/kg was used to demonstrate the
dose effect relationship, the 2.Smg/kg dosage was the primary
dose used.

The DFP for these two dosages was prepared in

peanut oil at a stock solution' concentration of 1 percent.
Both the 1.0 and 2.Smg/kg dosages were administered in the
neck region via the sub-cutaneous route.

LD 50 doses were

determined on mice with each new DFP preparation to ensure
constant potency from preparation to preparation.
dose of DFP used was 200pg.

The third

This dosage was prepared in
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physiological saline and injected via the intraventricular
route within 15 minutes from preparation.

The concentration

of the stock solution was 2.0mg/ml from which a lOOpl volume
(200µg) was used for the injection into the ventricle.
prepared in saline was found to have a pH of 3.61.

DFP

Injection

of such a low pH solution into the ventricle is definitely
not physiological.

However, due to the rapid decomposition

of DFP at the more basic pH's, no attempt was made to adjust
the pH of the DFP solution to that of cerebral spinal fluid
contained in the ventricle.

Feldberg (1958) in his studies

of intraventricular injection of DFP into cats, was made no
mention of any pH correction.

It was felt, however, ·that the

effects, if any, due to the low pH should be controlled.
Therefore, in the sham control rabbits receiving physiological
saline in place of DFP, the pH of the saline was adjusted
to that of the DFP solution, 3.61.
Atropine sulfate (AtSO ) was used at a dosage of 2.0mg/kg or
4
4.0mg/kg when used as part of a drug regime.
The drug
was dissolved in physiological saline and administered via
the intraperitoneal route.

'

Atropine methyl nitrate (AT.MN) was used at a constant
dosage of 2. Omg/kg when used as a part of a drug regime·.
The drug was dissolved in physiological saline and administered
via the intraperitoneal route.
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~eguence

of drug administration:

Eight major drug administration sequences were used in
these experiments; their sequences and their relationship to
the sacrifice time can be described as follows.

(1)

Animals

were sacrificed two hours after receiving either JB835 alone,
DOPA, or AT.MN alone.

(2)

Animals were sacrificed one hour

following DFP given alone at the dose of either 1.0 or 2.5
mg/kg.

(3)

Animals receiving JB835 and DOPA were given JB835

followed after 1 hour by DOPA and sacrificed 2 hours following
DOPA (3 hours after JB835).

(4)

Animals receiving either

JB835-, DOPA-, or ATMN with DFP were given DFP one hour
following the administration of one of the other members
of the combination and sacrificed 1 hour after the administration
of DFP (2 hours after

JB83~

DOPA, or AT.MN).

(5)

Animals

receiving the JB835-DOPA-DFP combination were given JB835
first followed at 1 hour intervals by DOPA and by DFP; they
were sacrificed 1 hour later (3 hours after JB835).

(6)

Animals receiving JB835-DOPA-DFP combination with either
AtSO or AT.MN were given JB835 followed at 1 hour intervals

4
by DOPA and either AtSO

or ATMN; DFP was administered 15 minutes

4
later and the animals were sacrificed 1 hour later (3 hours
15 minutes after JB835).

(7)

Animals receiving JB835-AtSO

4
DFP combination were given JB835 followed after 1 hour by
AtSO~and

after 15 minutes by DFP; they were sacrificed

1 hour later (2 hours 15 minutes after JB835).

(8)

The last
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group of animals were given JB835 followed at hourly intervals
bY DOPA and by DFP l.Omg/kg; they were sacrificed at intervals
of 1 hour, 2 hours, and 3 hours after DFP.
All of these dose cycles were adjusted so that animals
were always sacrificed at 2 P.M. + 30 minutes to avoid
possible circadian effects on the results.
animals receiving AtSO

In the case of the

or ATMN, the slightly longer dose

4
cycle was found to be without effect on the amine levels.

Isolation and removal of tissue samples:
Following decapitation the caudate nucleus and midbraindiencephalon were isolated and removed according to the
following procedure.

First, the left and right cerebral

hemispheres were separated and cut was made through the
left and right cerebral peduncles, liberating the left and
right hemispheres.

By carefully teasing the hippocampus

back, the entire caudate nucleus from head to tail was exposed.
Using a pair of toothed iris forceps, the caudate nucleus
was teased away from the ventricular wall.
The midbrain-diencephalon.,region is then easily obtained
by transecting the lower brain stem on a line from the
caudal end of the inferior colliculus to the rostral end
of the pons, thereby isolating the midbrain-diencephalon from
the rest of the brain stem.

Following removal of this brain

part, any vascular or connective tissue still connected

45

to the parts was removed and the parts rinsed free of blood
with distilled water.
For those studies in which individual brain parts were
used, their removal was as follows:

Hippocampus:

the hippo-

campus was rolled back and teased away from the neocortex
after the hemispheres have been removed from the rest of the
brain.

Midbrain:

the midbrain-diencephalon section was placed

on a glass plate and a sagittal cut was made down the center
of the tissue.

A transverse cut was then made along the

caudal border of the thalamus, separating the midbrain from
the diencephalon.

Thalamus and hypothalamus:

the diencephalon

was placed with the exposed inner surface dorsally positioned
on the glass plate.

The border between the thalamus and

hypothalamus was found and a transverse section made separating
the dorsal thalamus from the more ventral hypothalamus.
These dissections were easily made and identical areas were
always removed from the various brains sampled.
Catecholamine determinations:
The method for the determination of norepinephrine and
dopamine from a single tissue was described in part by

'

Carlsson and Waldeck (1958); Bertler et al.
Carlsson and Lindqvist (1962).

(1958); and

This method utilizes the

principles of ion-exchange column chromatography in .the
purification and separation of norepinephrine and dopamine.
Modifications of the original method were made for use in

46

The procedures used are as follows.

these studies.

Extraction of amines:
Immediately following removal, each tissue was weighed and
placed in a 15 ml ground glass hand homogenizer containing

a.o

mls. of 0.4 N. perchloric acid.

The homogenizer and acid

were prechilled and kept in an ice bath at all times to
minimize destruction of the amines by temperature.

Next, the

tissue was thoroughly homogenized and the homogenate poured
into a 12 ml. thick-walled conical centrifuge tube, also in
an ice bath.

An additional 3.0 mls. of the perchloric acid

were then added to the homogenizing vessel as a wash.

After

moving the pestle up and down the vessel several times, the
wash volume was poured into the homogenate.
At this time recovery standards are prepared.

4.0 mls. of

a homogenate made from brain tissue and perchloric acid were
added to each of two 12 ml. centrifuge tubes.

One tube

contained the standards and the other served as its tissue
blank.

To the standard tube, 3.0 mls. of the perchloric acid

was added.

Next, one ml. of norepinephrine standard at a

concentration of 1 µg/ml. was 'added to the standard tube,
as was one ml. of dopamine standard of the identical concentration.

To the tissue blank tube, 5.0 mls. of the perchloric

acid was added.

These two tubes, one containing the homogenate

plus standards and the other the homogenate alone, were treated
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identically with the regular brain samples.
The ice-cold centrifuge tubes were next centrifuged for
15 minutes at 3800 X g •.

Following centrifugation, the super-

natant was filtered using Watman #1 filter paper into a 15
ml. graduated conical tube kept in an ice bath.

After 30

minutes, the volume of filtered extract was measured and
recorded.

The tubes were then sealed and placed overnight in

a refrigerator.

column preparation:
The columns to be packeq with ion-exchange resin have been
adapted from 1.0 ml. disposable syringes.

It is necessary that

the internal diameter of the syringe barrel be 4.2-4.5 mm ••
The upper lip of the syringe was cut off and a 2 cm. piece
of tygon tubing affixed to the top of the syringe barrel in
such a way that one centimeter of tubing extended above the
top of the barrel.

This "column assembly" was then submerged

in a beaker containing distilled water.

It is necessary that

the actual packing of the column with resin be done under airtight conditions, as air bubbles will disrupt the uniform
packing of the resin.

•

Air bubbles were removed from the empty

column by inserting a stirring rod inside the column and
working it up and down a few times.

With the column completely

filled with water, a small ball of Pyrex glass wool was inserted
into the column and forced to the tip with a stirring rod.
This piece of glass wool serves to trap the resin within the
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column.

A two milliliter pipet is then filled with AG SOW

X4 200-400 mesh H+ form ion-exchange resin which has been
suspended in 0.01 M phosphate buffer plus 1 percent EDTA for
at least 24 hours.

The tip of the filled pipet was inserted

under water into the tygon tubing attached to the top of the
column.

The resin was then allowed to flow into the column.

After the resin bed has settled and a height of 50 mm. of
resin attained, another ball of Pyrex glass wool was inserted
into the top of the column, the resin bed now being contained
between the two glass wool retainers.

The freshly packed

columns were then mounted onto the "column board".

The

"column board" consisted of a 20 ml. graduated glass syringe
mounted firmly through a horizonal board which is secured to
ring stands.

A 3-way plastic stopcock was attached to the

tip of this syringe.

To the left of this syringe, a 20 ml.

plastic syringe barrel was mounted in similar fashion as the
glass syringe.

This plastic syringe barrel served as a reser-

voir through which the extract and other reagents can be
added to the column.

The reservoir and glass syringe are

connected through a series of

~lastic

stopcocks in a way

that liquids can be drawn into the glass syringe from the
reservoir.

On the open end of the stopcock attached to

the glass syringe, a plastic fitting was placed.

This fitting

allows for an air-tight seal to be made between the tygon
tubing on the column and the stopcock on the glass syringe.
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This fitting was made by removing the metal insert of a
disposable needle and using as the fitting, the upper plastic
portion.
Prior to attachment of the freshly packed resin column,
distilled water was drawn through the stopcock into the glass
syringe to remove any air from the stopcock.

With the distilled

water slowly dripping through the stopcock, the resin column
was fitted tightly onto the stopcock fitting.

The column

was now mounted in such a way as to allow for liquids to be
drawn into the glass syringe from the reservoir and then
to flow through the resin column.

The resin was next made

ready for addition of the tissue extracts by cycling the resin
from the H+ form to the Na+ form.

The cycling was accomplished

by passing 20 mls. of 0.01 M sodium phosphate buffer plus
1 percent EDTA at pH 6.5 through the resin at a flow rate
of one drop every 10 seconds.

After the buffer has passed

through the column the pH of the effluent was checked.

A pH

of 6.5 indicated that the column was cycled and ready to
receive the tissue extract.
Before adding the extract to the column, the pH was adjusted

'

to 6.5 using 5 N. potassium carbonate.

A brom phenol blue pH

indicator (pH 6.0) was added to the extract to speed up the
titration, although final pH was determined using short range
pH paper.

At pH 6.5, potassium perchlorate precipitates out

of the neutralized extract.

Storing for 10 minutes in the
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refrigerator increased the precipitation rate.

Following the

cooling, the extract was centrifuged at slow speed for 3
minutes to allow the precipitate to settle.

The extract was

then poured into the reservoir on the "column board", care
being taken not to allow the precipitate to enter the
reservoir.

The extract was drawn into the glass syringe and

allowed to flow through the resin at a rate of one drop
every 10 seconds.
After the extract has passed through the column, the resin
was washed with two 20 ml. volumes of distilled water.

The

flow rate for these two washed can proceed at a faster rate
than the extract.
Following the washes, the reservoirs were filled with 1
N. hydrochloric acid.

During the elution of the norepinephrine

and dopamine fractions, the flow rate for the hydrochloric
acid was maintained at one drop every 10 seconds.

The first

3 mls. of acid were passed through the column and. discarded.
The next 8 and 13 mis. of acid eluted the norepinephrine and
dopamine fractions, respectively.
of the 8 ml. norepinephrine

Following collection

f~action

and stored in the refrigerator.

the flasks were sealed

Flasks containing the dopamine

fractions were treated similarly.

Conversion of norepinephrine and dopamine to fluorophores:
It was necessary to convert both norepinephrine and dopamine
to their respective fluorophores before their respective
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concentrations could be determined using a spectrophotofluorometer.
separate conversion procedures were used for norepinephrine
and dopamine, adding another degree of specificity to the
method.

The chemical conversion of norepinephrine to nor-

~pinephrinachrome

to norepinephrinalutine (Bertler et al., 1958),

the actual fluorophore, was carried out as follows.

_s_

Std. RB

IS

TBf

Distilled water

3.80 3.90 2.90 2.80 2.90

0.01 M NaPO

0.50 0.50 0.50 0.50 0.50

buffer

(mls.)

4

pH 6.5
Neutralized eluate

---- ---- 1.00 1.00 1.00

pH 6.5 ·
0.10

Standard NE (lµg/ml)

0.10

0.5% Zinc sulfate

0.05 0.05 0.05 0.05 0.05

0. 25% K Fe(CN)

0.05 0.05 0.05 0.05 0.05

3

6

5 minutes
2

% ascorbic acid +

0.50 0.50 0.50 0.50

SN. NaOH
SN. NaOH

---- ---- ---- 0.45

•

10 minutes
2% ascorbic acid

---- ---- ---- 0.05

Upon completion of the above chemical procedure, the samples
were poured into reading tubes and read in an AMINCO spectra-
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photofluorometer at 400/505
wavelengths.

I11)l

uncorrected excitation/emission

The three tubes:

sample (S), internal standard

(IS), and tissue blank faded (TBf) comprised a set and were
used for each sample eluate.

Potassium ferricyanide was

used as the oxidant in this conversion procedure because of
its inability to convert dopamine to its respective fluorophore.

Such specificity added to the elimination of elution

cross-over contamination, if any.

The flurophore was found

to be stable for up to one hour.
Dopamine is similarly converted to dopaminachrome tq
dopaminalutine, the actual fluorophore (Carlsson and Waldeck,
1958).

The conversion procedure for dopamine is as follows.

Std.
Distilled water
Citrate-PO

s

-RB-

-IS-

TBu

3.05

3.30

1.30

1.05

1.30

buffer0.50

0.50

0.50

0.50

0.50

(mls.)

4
pH 5.4
Standard DA

0.25

0.25

(lpg/ml)
Unneutralized

1.65

'

eluate
Neutralized eluate----

2.0

2.0

pH 5.4
Na SO - NaOH soln.---2 3
0.02 N. Iodine
0.10

0.50
0.10

0.10

0.10

0.10

--..:......:....;~~_..;:;:~..;.._~~~~'--~~~~~~~~~~~~~~~-

(cont.)

53

Std.

-IS-

TBu

(mls.)

5 minutes
Na SO - NaOH soln.
2 3

0.50

0.50

0.50 0.50

5 minutes

1.60

5 N. Acetic acid

1.60 1.60

1.60
0.35

SN•

K CO

2

1.60

3

Place in boiling water bath for 15 minutes

After cooling the samples, they were poured into reading
tubes and read in the fluorometer at 330/380 mp uncorrected
excitation/emission wavelengths.

Although the dopamine

fluorophore is reported to be stable for 24 hours, all samples
were read in the fluorometer within one hour.

The boiling

water bath is used to increase the intensity of the dopamine
fluorophore in a shorter period than if it were left standing
at room temperature.
Due to inherent

variation~

from sample to sample the rate

of oxidation from one sample to the next varied when compared
to the oxidation rate of the standard which does not contain
tissue extract.

Since the standard is used as the reference

in determining the amount of amine present in each sample,
it is critical that the rate of oxidation of the standard
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'1

~'

and each tissue sample are identical.

Therefore, this method

employs the use of an internal standard for the sole purpose
of checking the sample rate of oxidation against that of the
standard; the sample values were always corrected so that
the standard and the sample had equal oxidation rates.
The formula for calculating the pg/gm concentrations of the
amines is as follows:
1 / 2 / 3
5

1.

6

7

1

4

= )lg/gm

wet weight tissue.

8

Net (sample - blank) sample fluorometer units corrected for
100% oxidation rate.

2.

Standard concentration (Jlg).

3.

Total eluate volume (ml) plus K CO volume (ml) used to
2 3
neutralize the eluate.

4.

Total volume of PCA (ml) used to homogenize tissue plus tissue
water volume (ml) (75% of the tissue weight).

5.

Net fluorometer units of the reference standard.

6.

Volume (ml) of the eluate used in the sample.

7.

Volume of the extract (ml) recovered after filtration.

8.

Tissue weight (gm).

'

Additional reference may be found in the literature cited.

Using the

fluoromete~

values obtained from the tissue standard

samples prepared with the brain samples, the percent recovery
of both norepinephrine and dopamine can be calculated.
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f'

Jwerage recoveries for norepinephrine were found to vary
between 70-80 percent, and those for dopamine between 5060 percent.

These recoveries are consistent with those

reported in the literature for this method.

Brain sample

pg/gm concentrations were always corrected for 100 percent
recovery based on the standard recoveries obtained with each
series of brain samples.

rntraventricular studies:
The first series of intraventricular injections of DFP
were performed on rabbits who had been anesthesized with
pentobarbital (30mg/kg, iv).

The second series of intra-

ventricular injections of DFP were performed on unanesthesized
rabbits, which were given 0.50 mls. of lidocaine (2.0mg/ml)
locally into the scalp.

With the exception of the anesthesia,

both groups of rabbits were treated identically.

With the

animals held in place by hand, the hair was clipped from the
top of the head.

In the case of the second group of rabbits,

lidocaine was now injected into the scalp.

A longitudinal

incision was made down the cen.J:.er of the scalp.

Using a

scalpel blade, the skull was cleared of muscle and connective
tissue on the left side of the midline suture near the
coronal suture.

Following removal of the surface tissue, bone

wax was applied to the skull to stop any bleeding from the
bone itself.

Next, using predetermined coordinates, a point

~
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~
~

r• was found which was 4.0 mm. caudal to the coronal suture and
~

~

F. 4 .5 mm. lateral to the midline suture.

At this point a small

~

hole was drilled using an electric Dremel Moto drill containing
a 1/32 inch drill bit.
bone.

Care was made to penetrate only the

Bone wax was then applied to the opening.

The rabbits

were replaced in their cages for a one hour period; allowing
them to settle down before beginning the drug regime.

The

actual surgical treatment did not produce any observable
signs of stress; the unanesthesized and the anesthesized
rabbits showed similar behavior following the recovery of
the latter from anesthesia.
After one hour had elapsed, the rabbits were given the first
in a series of drug treatments.
combinations used:
JB835-DOPA-ATMN-DFP.

There were three drug

JB835-DOPA-Saline; JB835-DOPA-DFP; and
The doses for JB835, DOPA, and ATMN,

as well as the administration sequences for all drugs
including DFP were described earlier.

The dose of DFP used

in these studies was 200pg contained in a constant volume
of 100)11.

The preparation of the DFP and saline used in

these experiments was describE\(l earlier.

A lOOµg dose of

DFP in a 100µ1 volume were previously used by Feldberg (1958)
in intraventricular injections.

In preliminary trials it

was found in these laboratories that the rabbits tolerated lOOpg and
200pg of DFP equally well via the intraventricular route,
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dose volume being constant.

It was decided on this basis

IC
f1

L'· and on that of preliminary neurochemical findings that 200)lg'

,.f..

of DFP in a dose volume of lOOpl would be used in the actual
experiments.

In the case of the sham operated control rabbits

receiving JB835-DOPA-Saline, the volume of lOOpl was injected
intraventricularly.
At the proper time in the administration cycle the intraventricular injection of either DFP or saline was carried out,
the rabbit again held securely in place.

Using a 250pl glass

syringe and a 27 gauge stainless steel needle, which had been
prepared to a length of 6.0mm., the 100µ1 volume was loaded
into the syringe.

Maintaining a vertical plane to the skull,

the needle was lowered through the wax-filled hole.

As soon

as the needle was fully inserted (up. to the flared portion of
the needle acting as a stop) the dose volume was slowly injected
into the lateral ventricle, the needle withdrawn, and the
hole immediately refilled with bone wax.

The animals were

then replaced in their cages for one hour and sacrificed.
Preliminary trials using various coordinates and injection
depths were performed to insufe that the described procedure
did place the dose volume within the left lateral ventricle.
Using Brom Phenol Blue, which stains the tissues it comes in
contact with, 100-SOOpl volumes were injected and the brains
removed and dissected, the location of the staining was then
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determined.

The 4.0mm. X 4.5mm. coordinates were found to

place the needle tip within the desired left lateral ventricle
as indicated by the complete staining of the walls of the left
lateral ventricle, as well as of the walls of the aqueduct and third
ventricle walls using the 100µ1 volume of the dye.

The 500µ1

dye volume stained the walls of all ventricles and the
aqueducts associated with them.

Repeated trials were performed

and each time the dye was observed only on the walls of the
ventricular system.

Other coordinates do appear in the

literature for intraventricular injections.

A variety of

coordinates could be used since the left lateral ventricle
runs parallel to the midline suture; however, in these studies
the 4.0mm. X 4.5mm. coordinates were found preferable.

As

an additional precaution, while dissecting the brain parts
out, visual location of the entry point of the needle was evaluated to verify entry into the ventricle, the surrounding
tissues were inspected as well to be sure that the needle
did not enter one of these tissues.

Injection into the left

lateral ventricle was visually confirmed in all animals receiving
an intraventricular injection.'
Some comment should be made regarding the symptomatology
of the rabbits following intraventricular injection of DFP,
Due to the pretreatment of JB835-DOPA, the animals exhibited
piloerection, hyperreflexia, and mydriasis.

Following intra-

ventricular administration of DFP, the animals began to exhibit
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intermittent seizures beginning after about 5 minutes.
'

These

.

seizures consisted of leg jerking, rolling over, and spinning
in a clockwise or counterclockwise direction which varied
from rabbit to rabbit.

This seizure period lasted for from

5-10 minutes after which the rabbits assumed a fixed position;
some animals rocked back and forth while in this position.
During the remaining time the rabbits exhibited a chewing jaw
motion; one actually bit its tongue enough to cause bleeding.
In addition, the rabbits seemed to have a lowered threshhold to
audiogenic seizures; a loud sound caused sudden short bursts
of leg jerking.

Most of the rabbits salivated during the

latter half of the post-drug period.

DFP did not produce

miosis in any of the animals when given via this route.
Piloerection disappeared and the hair remained flat.
muscle fasciculations were not observed.

Skeletal

Feldberg (1958)

reported similar behavorial symptoms in cats given DFP intraventricularly.
These symptoms differed in many respects to those seen
following DFP via the subcutaneous route.

When DFP was given

subcutaneously, miosis always fCCurred (except when atropine
treatment was employed), there was no apparent change in
audiogenic seizure threshhold, skeletal muscle fasciculations
were observed, the rabbits did not assume a fixed position,
did not rock back and forth or spin in either clockwise or
counterclockwise direction.

Sham-operated control rabbits
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receiving 100µ1 of saline at pH 3.61 did not exhibit any of
the symptoms seen following DFP in either anesthesized or
unanesthesized rabbits; in fact their behavior was identical
to that of rabbits receiving JB835-DOPA, but not treated
surgically •.

fholinesterase activity assay:
Cholinesterase activity was measured in control rabbits
(no drugs), in rabbits treated with JB835-DOPA; JB835-DOPADFP; and JB835-DOPA-AtSO -DFP combinations. The doses and
4
drug administration sequences were already described. Cholinesterase activity was measured in midbrain, thalamus, hypothalamus, and caudate nucleus; two separate samples of each
part were used in each drug group.

The method used for

measurement of the cholinesterase activity was previously
described by Ellman et al.

(1961).

The procedure was as

follows. The animals were pretreated with the above mentioned
drug combinations or given no drugs in the case of the control
rabbits; they were sacrificed and the brain areas removed as
described earlier.

After weighing the individual brain parts,

' 0.10 M phosphate buffer,
they were homogenized in ice-cold
pH 8.0.

All tissues were homogenized to a final weight/volume

concentration of 20mg/ml ••

The 20mg/ml. homogenates were kept

in an ice bath until ready for the cholinesterase assay.
In pretrial experiments it was found that the 400pl homo-
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genate volume described by Ellman et al. was not satisfactory
for the control rabbit assays, as the cholinesterase activity
in control rabbit brain parts was too high for an accurate
measurement when the 400µ1 volume was used.

200µl's of

homogenate was found to be acceptable and was used in these

•
assays.

To control for color formation due to other than

cholinesterase materials, an eserinized blank was run with
the tissue sample, both containing the same volume of homo-

-5
genate.

The 3 X 10

M dose of eserine was reported to

inhibit 100 percent of the acetylcholinesterase activity while
only inhibiting 25 percent of the butrylcholinesterase activity,
thus after subtraction of the blank activity from the sample
activity, the cholinesterase activity remaining would represent
primarily only that due to acetylcholinesterase.

During

each enzymatic assay, a DFP-treated brain part and its respective
blank were run together with an identical non-DFP treated
brain part.

Thus, not all DFP brain samples were run together,

a system that could induce error.

Over the course of the

enzymatic study, brain parts from animals treated with JB835DOPA-DFP and JB835-DOPA-AtSO

-~FP

drug combinations were run

4
against identical brain parts from both control (no drug)
animals, as well as JB835-DOPA treated animals.
The sequence of events for each enzymatic measurement were
as follows.

The Beckman DU spectrophotometer absorbancy wave-
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length was set for 412 mµ as described by Ellman et al •• After
an adequate warm up period (1 hour), the sensitivity and
dark current was adjusted such that the null indicator read
zero.

A standard quartz photocell containing 0.10 M phosphate

buffer pH 8.0 was used to make these adjustments.

Next,

the photocells were removed and 200pl of homogenate was added
to the sample and to blank photocells.

To the blank photocell

lOOpl of eserine was added producing a final volume concentration
. -5

of 3 X 10

M, which inhibited all of the acetylcholinesterase

activity and 25 percent of the butrylcholinesterase activity.
To each photocell 100µ1 of DTNB (Di-thio-bis nitrobenzoic acid)
was added and the reagents in the cell mixed by blowing air
bubbles through the cell.

The photocells were replaced in

the cell housing of the photometer.

The increasing absorbance,

owing to DTNB's reaction with non-specific cholinesterases, i.e.
thiolesterases, and protein, was monitered until a peak absorbance was reached.

Using the slit adjustment knob, the null

needle was returned to zero.

The photocells were again

removed from the cell-housing and 200µ1 of acetylthiocholine
substrate was added to each cell and mixed with air bubbles.

'

A 10 second interval was maintained between the cell sequence
so that a proper timing sequence could be maintained during
subsequent absorbancy measurements.

The photocells were

quickly replaced in the photometer and absorbancy measurements
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of each cell made at 1, 2, 4, and 6 minute intervals.

When

all samples had been run for that day (3 hours after the first
measurement), the first sample was rerun to check for loss
of enzyme activity.

No loss of enzyme activity was observed

over the testing period.
It was found that the caudate nucleus tissue samples from
control and JB835-DOPA treated rabbits had, at six minutes,
surpassed the maximum absorbancy measurable.

To stay within

the linear portion of the absorbancy curve, the four minute
absorbancy value, minus the respective blank value, was
used to calculate the mean change in absorbance/minute for all
samples.

From this value the average change in absorbance/

minute was determined for each pair of brain parts within
each drug group.
The JB835-DOPA treated rabbits served as the sham control
'

group and the mean acetylcholinesterase activity for each
part within this group was considered to represent 100 percent
cholinesterase activity with respect to the two DFP treated
groups.

The rate of hydrolysis (moles of substrate hydrolyzed/

minute/gram of tissue) of acei:Jylcholinesterase was calculated
using the formula described by Ellman et al.

(1961).

Acetylcholine bioassay;
Acetylcholine levels of rabbit brain thalamus, hypothalamus,
midbrain, and caudate nucleus were measured using bioassay
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techniques on guinea pig ileum.

Animals were pretreated with.

JB835-DOPA; JB835-DOPA-DFP; JB835-DOPA-AtSO -DFP; JB835-DOPA4
ATMN-DFP drug combinations; control animals (no drugs) were
also used.

The doses and administration sequences have been

described earlier.

The bioassay procedures used were based

on methods described by Magnus (1904); Turner (1965); and
Livingston (1968) with modifications by Kindel (1971).
Following drug pretreatment, the animals were sacrificed and
the brain parts were removed as described earlier.

Once

removed the individual brain parts were quick-frozen in liquid
nitrogen.

To prechilled homogenizing vessels, 4 mls. of

eserinized (20pg/ml) bicarbonate-free Locke Ringer solution
with 1/15 M sodium phosphate monobasic buffer pH 6.68-7.30
are added.

The ratio of bicarbonate-free Locke Ringer and

1/15 M sodium phosphate monobasic buffer was 3.333/1.000.
To the 4 mls. of buffer solution, 0.5 mls. of 0.333 N. hydrochloric acid was added and the two solutions mixed.

The first

brain part was removed from the liquid nitrogen, weighed, and
placed into the homogenizing vessel.

The tissue was homogenized

using a power driven pestle for 2-3 minutes keeping the homo-

'

genizing tube in an ice bath during the entire procedure.
After homogenization, the homogenate was placed in a boiling
water bath for 10 minutes.

Upon removing the vessel from

the water bath, the homogenate was mixed using a Vortex mixer
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that any tissue residue on the upper walls of the vessel

was mixed in with the homogenate.
allowed to cool.

The homogenate was then

Once cooled, the homogenate was poured into

a thick-walled centrifuge tube.

1.0 ml. of cold distilled

water was then added to the homogenizing vessel as a wash.
After swirling in the vessel, the wash was added to the
homogenate in the centrifuge tube.

The homogenate was then

centrifuged for 15 minutes at 3800 X g ••

Following centrifug-

ation, the supernatant was poured into another centrifuge
tube and the tissue pellet re-extracted with 1.0 ml. of the
bicarbonate-free Locke Ringer solution without eserine.

~he

re-extracted homogenate was centrifuged for 15 minutes at
3800 X g ••

The supernatants from both the first extraction

and the re-extraction were pooled and neutralized to pH 6.87.0 with 0.333 N. sodium hydroxide.
was then centrifuged at 3800 X g ••

The neutralized extract
The supernatant was poured

into a centrifuge tube containing alpha chymotrypsin (400pg/ml
of extract).

The extract and chymotrypsin were mixed, the

centrifuge tube stoppered, and the extract incubated for 10
minutes at 38 degrees Centigrade in a dry incubator.

'

After

the incubation, the volume of the extract was measured and
recorded.

2.5 mls. of the extract was removed and added to

another centrifuge tube to be used later with acetyicholine
standard.

The sample extract was then stoppered and frozen
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until bioassayed.
0.40 mls. of 0.333 N. sodium hydroxide was then added to
the 2.5 mls. of extract isolated for use with acetylcholine.
The two solutions were mixed and the extract incubated in a
boiling water bath for 10 minutes.
any acetylcholine present.

This procedure destroys

After boiling, the extract was

cooled and centrifuged for 15 minutes at 3800 X g ••

The

supernatant was poured into a centrifuge tube and neutralized
with 0.333 N. hydrochloric acid to pH 6.8-7.0.

The neutralized

extract was stoppered and frozen for later use.
Simply stated, the extraction steps include:

(1)

homogenization

of the tissue and acid extraction of the acetylcholine.

(2)

heating of the homogenate to destroy all cholinesterase present
in the tissue.

(3)

centrifugation and re-extraction of the

tissue pellet.

(4)

neutralization of the extract.

(5)

of chymotrypsin to the extract which destroys substance
aided by incubation.

(6)

addition
11

P 11 ,

bioassay of the acetylcholine present

in the tissue extract on guinea pig ileum.

Bioassay:

'
Tyrode solution was prepared
with lpg/ml. of morphine,
0.2pg/ml. of pyrilamine, and 0.03µg/ml. of dibenzyline.

Morphine

was used to decrease spontaneous activity of the ileum:
pyrilamine and dibenzyline blocked any histamine and serotonin,
respectively, still present in the extract.
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The guinea pig was sacrificed by a blow on the head.

The-

ileum was isolated, removed, and flushed with Tyrode solution.
A piece of the ileum was then mounted in the 5 ml. organ bath
aerated with 5 percent CO

and 95 percent
2

o .

A lOOµg dose

2

of acetylcholine was used to test the sensitivity of the
preparation.

If sensitive, the preparation was allowed to

stand for one hour to allow its accomodation to the bath.
Using acetylcholine, a dose producing a maximal response
of the ileum was found as well as a dose producing 75 percent
of maximal response.

Repeated doses of the latter dose were

given to assure a constant response.

Using the tissue extract,

which has been allowed to thaw, the volumes necessary to induce
a high and low effect were found; the high "dose" was capable
of double the response seen with the low "dose".

With these

two extract responses established, doses of authentic acetylcholine were found which mimicked the two responses produced
by the tissue extract.

These two doses of authentic acetyl-

choline were used repeatedly to assure constant ileum responses.
An amount of acetylcholine is then added to the 2.5 mls. of
extract which had been put aside for the acetylcholine

'

standard, the high and low "dose" volumes from this standardextract preparation capable of inducing approximately the
high and low "dose"

(volume} responses produced by the tissue

extract we've selected.

After establishing that the responses

to the acetylcholine-extract standard and the tissue extract
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were constant, a latin square was completed.

From the latin

square data, acetylcholine levels in the various brain parts
were calculated and expressed as pg/gm (Livingston, 1968).
Upon completion of the latin square, serotonin and histamine
were added to the bath to assure that responses to both were,
still blocked by the blocking agents added to the Tyrode
solution.

statistics:
The statistical analysis of the data presented in this
dissertation was carried out by means of the unpaired Student
"t" test, the samplings corning from two groups of rabbits.
The degrees of freedom used in the establishment of the
probability (P) values were n-1 for each group with the
total degrees of freedom being n-2.

Statistical significance

of the data was accepted when the "P" value was 0.05 or less.
In some cases where the sample size was small and there was a
drug-induced shift in the mean value, "P" values of 0.100.05 were shown.

Although this value does not indicate

statistical significance as per standards established for

'
statistical analysis, it was felt
that a clear trend was
indicated in the case of the data in question; had large
sample sizes been used, statistical significance would have been
proven.
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RESULTS

-

The effects of JB835 and DOPA on norepinephrine and dopamine

-1evels.
As expected, it was found that either JB835 or DOPA increased
the levels of norepinephrine over their control concentrations
in both caudate nucleus and in the midbrain-diencephalon; the
dopamine levels were increased at least in the case of the
former (Table I).

In the case of the caudate nucleus, JB835

increased the levels of norepinephrine and dopamine by 52
and 19 percent respectively.

Similar increases in norepinephrine

occurred in the case of the midbrain-diencephalon, JB835
inducing a 52 percent increase and DOPA- a 16 percent increase.
However, the concentration of midbrain-diencephalon dopamine
was not increased above control levels by either JB835 or
DOPA (Table II).
Furthermore, DOPA-JB835 combinations induced even more
pronounced increases in the levels of norepinephrine in both
the caudate nucleus and in the midbrain-diencephalon area

•

(by 55 and 270 percent, respectively).

Also, this dose

combination induced an increase of dopamine levels in the case
of the caudate nucleus which was significantly greater than
that induced by JB835 or DOPA alone (Table I; Fig_ure I).
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Moreover, while neither the monoamine inhibitor nor DOPA,
employed alone, increased the level of dopamine in the case
of the midbrain-diencephalon, their combination induced a
significant increase of dopamine in this area (Table II: Figure
2) •

The effect of DFP on norepinephrine and on the dopamine levels
in otherwise non-treated and pretreated animals.
With this background of information, DFP was employed at
two dose levels, 1.0 and 2.5 mg/kg, in rabbits otherwise not
treated, or pretreated with the DOPA-JB835 combination.

It

was of interest that DFP affected significantly dopamine
and norepinephrine levels only in pretreated animals, i.e.

/•'

in the rabbi ts which were "loaded", following the appropriate
pharmacological maneuvers, with the catecholamines.
In animals which were not pretreated with DOPA and/or the
monoamine oxidase inhibitor, neither dose of DFP induced a
significant change in norepinephrine and dopamine, whether
in the case of the caudate nucleus or of the mid.braindiencephalon region (Figures 3 and 4).

Slight increases in

norepinephrine were recorded with both doses of DFP in the
case of the midbrain-diencephalon, and with the larger
dose of DFP in that of the caudate nucleus; a relatively
large but statistically not significant decrease in norepinephrine
was found following 1.0 mg/kg dose of DFP in the case of the
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TABLE I
Effects of DFP in the Caudate Nucleus on Norepinephrine (NE)
and Dopamine (DA) Levels.
Mean DA +
- S.E.

No.

4

8.913

;!;

1.339

6

0.083

6

6.841

;!;

0.938

6

~

0.117

4

7.162

±

0.762

4

0.238

±

0.016

4

5.904 ± 0.497

5

JB835 + DOPA

0.592

±

0.054

8

8.306

±

0.568

10

JB835 + DOPA + DFP

0.221 ± 0.028

9

9.110

±

0.809

10

Control

0.328

±

8

6.004 ± 0.579

15

Drug*

Mean NE ± S.E.

DOPA

0.438

;!;

0.032

DOPA + DFP

0.322

;!;

JB835

0.498

JB835 + DFP

*

**

0.069

No.**

JB835, 6 mg/kg (ip}; DOPA, 50 mg/kg (ip}; DFP, 2.5 mg/kg (sc).
The controls were given saline.

S.E.

=

standard error; No.

=

'

number of individual determinations.
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TABLE II

Effects of DFP in the Midbrain-Diencephalon on Norepinephrine (NE}
and Dopamine (DA} Levels.

Drug_

Mean NE +
- S.E.

No.

Mean DA ± S.E.

No.

DOPA

0.393 ± 0.035

6

0.225 ± 0.047

4

DOPA + DFP

0.226

±

0.033

6

0.199 ± 0.053

6

JB835

0.513 ± 0.100

4

0.142 ± 0.024

4

JB835 + DFP

0.243 ± 0.084

6

0.394 ± 0.107

5

JB835 + DOPA

0.910 ± 0.141

8

0.377 ± 0.073

8

JB835 + DOPA + DFP

0.362 ± 0.055

11

0.875 ± 0.151

10

Control

0.336 ± 0.035

19

0.257 ± 0.045

11

For other explanations, cf. Table I •
.•

.-.

"
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LEGEND FOR FIGURE I

Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with
or without DFP (2.5 mg/kg,sc); and DFP alone (2.5 mg/kg,sc}
on caudate nucleus norepinephrine and dopamine levels.
control values are indicated with the horizontal line.

Values

are expressed as the Mean + the standard error and represent
4-10 individual determinations.

The level of significance

was calculated using Student's test.
o indicates P(0.001 for the difference between bargraphs
2 and 3.

•
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LEGEND FOR FIGURE 2

Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip),
with or

without DFP (2.5 mg/kg,sc); and DFP alone (2.5 mg/kg,

sc) on midbrain-diencephalon

norepinephrin~

and<bpamine

levels. Control values are indicated by the horizontal line.
Values are expressed as the Mean + the standard error and
represent 4-10 individual determinations.

The level of

significance was calculated using Student's test.

+ indicates P(0.005 and • indicates P(0.025 for the difference
between bargraphs 2 and 3 in the upper and lower horizontal
rows, respectively.
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LEGEND FOR FIGURE 3

Effect of DFP (1.0 and 2.5 mg/kg, sc); and JB835 (6 mg/kg,
ip) plus DOPA (50 mg/kg, ip), with and without DFP (1.0 and
2.5 mg/kg, sc) on caudate nucleus norepinephrine and dopamine
levels.

Values are expressed as the Mean + the standard

error and represent 4-10 individual determinations.

Control

levels (not shown) are 0.328 + 0.069 and 6.004 + 0.579 for
norepinephrine and dopamine respectively.

Significance was

calculated using Student's test.
•indicates P<0.005 for the difference between bargraphs
3 and 4; o indicates P<0.001 for the difference between
bargraphs 3 and 5.

79

------- -----

------ ----------------------------------------------------------------------

,,,,,, ..

MIDBRAIN - DIENCEPHALON
1 -00
0

NOREPINEPHRINE

0 80

0-60

•

0-40

0-20
0.00

1.00
DOPAMINE

o.ao

•

0.60

0.40

0-20
0.00
•
0

(.0. 025

(o .oos

.

....
0

~

0

.......

FIGURE 4

,,

~

..

...•
.....•

03

.

8

>

>

...

.

+

+

+

0

0

>

'

... •...•

...
...

••

~ w

0

+

+

.

---- -

80

LEGEND FOR FIGURE 4

Effect of DFP {1.0 and 2.5 mg/kg, sc); and JB835 (6 mg/kg,
ip) plus DOPA {SO mg/kg, ip), with and without DFP {1.0 and
2.5 mg/kg, sc) on midbrain-diencephalon norepinephrine and
dopamine levels.

Values are expressed as the Mean + the

standard error and represent 4-10 individual determinations.
Control levels {not shown) are 0.336 + 0.035 and 0.257 +
0.045 for norepinephrine and dopamine respectively.
Significance was calculated using Student's test.
• indicates P(0.025 for the difference between upper bargraphs
3 and 4, and also lower bargraphs 3 and 5.

o indicates

P~

0.005 for the difference between upper bargraphs 3 and 5.
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iatter.

The changes in dopamine levels induced by DFP

whether in the case of the midbrain-diencephalon area or
· of the caudate nucleus were even less marked than those in
norepinephrine concentrations (Figures 3 and 4) •
To the contrary, in "loaded" animals, i.e. in the animals
in which the levels of norepinephrine and of dopamine were
increased by the pretreatment, DFP (2.5 mg/kg) produced a
significant change with respect to the "loaded" state in both
the monoamines in the case of the caudate nucleus as well as
in that of the midbrain-diencephalon region when employed at
the larger dose; the smaller dose of DFP exerted less of an
effect, although the trend of the data was similar with both
doses of the anticholinesterases.
Perhaps surprisingly, the general direction of the changes
was toward increased levels of dopamine and decreased levels
of norepinephrine.

These changes were generally more pro-

nounced in the case of the midbrain-diencephalon area than
in that of the caudate nucleus; moreover, the magnitude of
the change induced by DFP relative to the "loaded" state was
generally greater in the case

~f

the animals pretreated by

JB835 than in that of the animals pretreated by DOPA (Figures
5 and 6), while the maximal change due to DFP was found in
the case of animals pretreated with the JB835-DOPA combination
(Figures 1 and 2).

It should be noted that this was also

the order of the increase in norepinephrine or dopamine levels
induced by DOPA, JB835, and JB835-DOPA combination (Table II,

r-
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,,~

Figures 2 and 6).
Specifically, the results in question were as follows
(the percent change in monoamines induced by DFP after
DOPA, JB835, or JB835-DOPA treatment represent the change
relative to the monoamine levels in similarly pretreated
animals that were not given DFP):
~idbrain-diencephalon

In the case of .the

area, DFP, at 2.5 mgjkg, induced a 53

percent decrease in norepinephrine level in the animals
pretreated by JB835, while 43 percent decrease in norepinephrine
was noted following the pretreatment with DOPA.·

In the case

of the animals pretreated with DOPA and JB835 a 60 percent
decrease was noted following 2.5 mg/kg DFP.

Somewhat less

consistent data were obtained with regard to dopamine, although
generally an increase in this monoamine was noted.

A small

(12 percent) decrease was noted after DFP (2.5 mg/kg) in
the case of the DOPA-pretreated rabbits, while a very marked
increase in dopamine occurred in the case of the animals
pretreated with JB835 or with the JB835-DOPA combination:

a

177 percent increase was found in the former case following
the 2.5 mg/kg dose of DFP, an<\ a 135 percent increase was
recorded with the 2.5 mg/kg dose of DFP following the JB835DOPA pretreatment.

It should be noted that in this case the

change following the JB835-DOPA pretreatment was somewhat
smaller than that following pretreatment with JB835 alone.
However, the increase in dopamine levels of the mid.brain-
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LEGEND FOR FIGURE 5

Effect of JB835 (6 mg/kg, ip); and DOPA (50 mg/kg, ip),
with or without DFP (2.5 mg/kg, sc) on caudate nucleus
norepinephrine and dopamine levels.

Values are expressed as

the Mean + the standard error and represent 4-6 individual
determinations.

Control values (not shown) are 0.328 + 0.069

and 6.004 + 0.579 for norepinephrine and dopamine respectively.
The level of significance was calculated using Student's
test.
•indicates P(0.10-0.05 for the difference between bargraphs
3 and 4.
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LEGEND FOR FIGURE 6

Effect of JB835 (6 mg/kg, ip); and DOPA (50 mg/kg, ip),
with or without DFP (2.5 mg/kg, sc) on midbrain-diencephalon
norepinephrine and dopamine levels.

Values are expressed

as the Mean + standard error and represent 4-6 individual
determinations.
and 0.257

±

Control values (not shown) are 0.336 + 0.035

0.045 for norepinephrine and dopamine respectively.

The level of significance was calculated using Student's
test.
o indicates P<0.01 for the difference between bargraphs
1 and 2;

& indicates P(0.10-0.05 for the difference between

bargraphs 3 and 4 in both the upper and lower horizontal rows •

•
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diencephalon area in the "loaded" state of the animal was

very pronounced; it coresponded to almost a two-fold change
compared to the controls and it was much more marked than that
recorded in the "loaded" animals in the case of the caudate
nucleus (Table 1).

In this situation, DFP may have saturated

the capacity of the midbrain-diencephalon area as it elevated
thecbpamine levels to 0.875 microgm./gm. compared to the
0.257 microgm./gm. level of the controls (Table 2).
In the case of caudate nucleus, DFP induced, similarly,
marked decreases in norepinephrine in pretreated rabbits.

A

26 and a 52 percent decrease were found with the 2.5 mg/kg
dose of DFP in animals pretreated with DOPA and JB835,
respectively; an even greater change occurred in animals
pretreated with a JB835-DOPA combination, as the decrease
with this dose of DFP amounted to 63 percent; a 13 percent
decrease was noted following the smaller dose of 1.0 mg/kg.
The DFP-induced changes in dopamine levels of the caudate
nucleus were less consistent than those in the norepinephrine
levels.

DFP (2.5 mg/kg) induced relatively small ·.. decreases

in dopamine level following

"~·.

ei~her

DOPA (23 percent) or JB835

(18 percent); however, under maximal loading conditions,
i.e~

after JB835-DOPA pretreatment, a small increase (9 percent)

in the levels of dopamine was noticed (Table l); none of these
changes were statistically significant.

r
~

f
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!!l-e effects of atropine and atropine methyl nitrate.

,,

It may be expected that the effects of DFP on dopamine and/
or norepinephrine were due to accumulated acetylcholine; in
fact, results indicating the occurrence of such an accumulation
'have been obtained (cf. below section "acetylcholine levels").
It may be then further surmised that atropine should block
the effects of DFP on the monoamines, while the quaternary
atropine, atropine methyl nitrate, which does not readily
penetrate into the brain, should be less effective in this
respect.

Pertinent experiments were therefore carried out

under maximal "loading" conditions, i.e. following the pretreatment with JB835-DOPA combination.
The results were not always as expected.

The DFP-

induced decrease in the norepinephrine levels of either the
caudate nucleus or of the midbrain-diencephalon area was partially
blocked by 48 and 64 percent, respectively with atropine,
2.0 mg/kg, given i.p. prior to DFP (Figures 7 and 8).
Similarly, atropine prevented, at the same dose, most of the
increase in dopamine due to DFP in the case of the midbraindiencephalon level (Figure 8).

"

However, the effect of DFP

on the dopamine levels' of the caudate nucleus was not effected
by atropine (Figure 7).

It should be pointed out however

that, in the case of the caudate nucleus, the effect of DFP
on the levels of dopamine following pretreatment with JB835· DOPA combinations was statistically not significant (cf. above,

!::•

11
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LEGEND FOR FIGURE 7
I
Effect of JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip),
with and without DFP (2.5 mg/kg,sc) or atropine sulfate
(2.0 mg/kg, ip) and DFP (2.5 mg/kg, sc) on caudate nucleus
norepinephrine and dopamine levels.

Values are expressed

as the Mean + the standard error and represent 4-10 individual
determinations.
line.

Control values are indicated by the horizontal

Significance was calculated using Student's test.

o indicates P<0.001 for the difference between bargraphs 1
and 2; • indicates P(0.05 for the difference between bargraphs
2 and 3.
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LEGEND FOR FIGURE 8

I
Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip),
with and without DFP (2.5 mg/kg, sc) or Atropine sulfate (2.0
mg/kg, ip) and DFP (2.5 mg/kg, sc) on midbrain-diencephalon
norepinephrine and dopamine levels.

Values are expressed as

the Mean + the standard error and represent 4-10 individual
determinations.
line.

Control values are indicated by the horizontal

Significance was calculated using Student's test.

• indicates P<0.01 for the difference between bargraphs 2 and
3.

The bargraphs 1 and 2 in both horizontal rows also differed

significantly(cf. Figure 1).

'
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Figure 1).
Even more surprising were the results obtained with atropine
methyl nitrate (2.0 mg/kg), given i.p. prior to DFP, to
rabbits under maximal "loading" conditions.

While the

quaternary atropine did not, as expected, block significantly
the DFP effect on the levels of norepinephrine and of dopamine
in the case of the caudate nucleus (figure 9), and while
similarly it did not prevent the DFP-induced decrease of the
level of norepinephrine in that of the midbrain-diencephalon
·region, most unexpectedly it afforded complete protection
against DFP-induced, otherwise marked increase in the midbraindiencephalon dopamine (Figure 10) •

In fact, while both ·

atropine and quaternary atropine exhibited a similar blocking
action upon the DFP-induced increase of dopamine in the midbraindiencephalon region, the effect of the latter was much more
pronounced.
It should be finally added that methylatropine (cf. Figures
9 and 10) given alone (without DFP) to rabbits did not have
any significant affect on the levels of either monoamines.

'

Time characteristics of the effect of DFP on norepinephrine
and on dopamine.
A possible explanation regarding the DFP-induced decrease
in norepinephrine and elevation of dopamine observed in
. animals pretreated with JB835-DOPA combinations (Figures 1 and
2) could be the inhibition of dopamine-,4-hydroxylase, the
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LEGEND FOR FIGURE 9

I

Effect of atropine methyl nitrate (2.0 mg/kg, ip); and
JB835 (6 mg/kg, ip) plus DOPA (SO mg/kg, ip), with or without
DFP (2.5 mg/kg, sc) or atropine methyl nitrate (2.0 mg/kg, ip);
and DFP (2.5 mg/kg, sc) on caudate nucleus norepinephrine
and dopamine levels.

Values are expressed as the Mean + the

standard error and represent 4-10 individual determinations.
Control levels are indicated by the horizontal line.

Statistical.

significance was calculated using Student's test.
o indicates P<0.001 for the difference between bargraphs 1
and 2.

'
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LEGEND FOR FIGURE 10

I

Effect of atropine methyl nitrate (2.0 mg/kg, ip); and
.JB835 (6 mg/kg, ip) plus DOPA (50 mg/kg, ip), with or without
DFP (2.5 mg/kg, sc) or atropine methyl nitrate (2.0 mg/kg, ip};
and DFP (2.5 mg/kg, sc) on midbrain-diencephalon norepinephrine
and dopamine levels.

Values are expressed as the Mean + the

standard error and represent 4-10 individual determinations.
Control levels are indicated by the horizontal line.

Signifi-

cance was calculated using Student's test.
• indicates P(0.05 for the difference between bargraphs 2 and
3.

Bargraphs 1 and 2 in both horizontal rows also differed

significantly (cf. Figure 1).

'
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enzyme responsible for the conversion of dopamine to norepinephrine
within the storage granules (Weiner, 1970).

r

1·
~·

t~·

f):

By inhibiting

this enzyme, DFP would allow dopamine levels to increase
while norepinephrine levels, after norepinephrine was released
If such

following the DFP treatment, would be lowered.

conditions were occurring, norepinephrine levels would approach
I

a depleted state over a period of time, while dopamine levels
would be elevated.

To investigate this possibility, a study

was undertaken in which norepinephrine and dopamine levels
·

were measured in animals pretreated with JB835-DOPA combination
given DFP, 1.0 mg/kg, at intervals of one, two and three hours
following DFP.

The 1.0 mg/kg dose of DFP was used as in the

course of this long-time experiment, the larger dose of DFP
induced delayed toxicity which may have effected, nonspecifically,
the results.
In the case of the midbrain-diencephalon, one hour following
DFP, norepinephrine levels were 75 percent of those levels in
rabbits pretreated with only JB835 and DOPA (Figure 11).
Dopamine levels at one hour were only slightly elevated over
those treated with JB835 and

D~PA.

Two hours following DFP,

however, both the decrease in norepinephrine and elevation
in qopamine levels became more apparent; norepinephrine levels
20 percent less than one hour after DFP, while dopamine levels
Were 45 percent above the one hour levels.

It would appear

that the time shift on the maximal effect due to 1.0 mg/kg of
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I
LEGEND FOR.FIGURE 11

Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with
or without DFP (1.0 mg/kg, sc) on midbrain-diencephalon
norepinephrine and dopamine levels.

Amine levels were measured

at 1, 2, and 3 hours following DFP.

Values are expressed as

the Mean + the standard error and represent 3-8 individual
determinations.

Control levels (not shown) are 0.336 + 0.035

and 0.257 + 0.045 for norepinephrine and dopamine respectively.
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pFP as compared to that of 2.5 mg/kg dose of DFP, might reflect
a slower rate of cholinesterase inhibition and relatively lower
acetylcholine levels.

Three hours following DFP, the nor-

epinephrine levels were no longer decreasing, but rather
increasing (Figures 11 and 12).
~

..

Similarly, dopamine levels

stopped increasing and were on the decline (Figures 11and12).
I

It has been reported that the time required for conversion
of dopamine to norepinephrine by dopamine-.4-hydroxylase is
much longer, than that needed for the conversion of dopamine
from DOPA,

(hours versus minutes, Spector et al., 1959).

It

is interesting that one hour following the maximum dopamine
elevation the norepinephrine levels began to increase.

Since

norepinephrine levels did not continue to decrease to a
depleted state and dopamine levels declined three hours
following DFP, it may be concluded that the DFP-induced decrease
in norepinephrine and elevation in dopamine is not due to
inhibition of

dopamine-~-hydroxylase

by DFP.

The effects observed in the caudate nucleus (Figure 12) at
various times after 1.0 mg/kg of DFP in rabbits pretreated
with JB835 and DOPA differed markedly from the effects seen in

"

the midbrain-diencephalon region.

Norepinephrine levels

continuously decreased one, two, and three hours following
DFP.

One hour following DFP, the caudate nucleus dopamine·

levels were slightly lower than the levels in rabbits treated
with only JB835 and BOPA.

Two hours following DFP a 40 percent
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LEGEND FOR FIGURE 12

/

Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with
or without DFP (1.0 mg/kg, sc) on caudate nucleus norepinephrine
and dopamine levels.
3 hours following DFP.

Amine levels were measured at 1, 2, and
Values are expressed as the Mean +

the standard error and represent 3-10 individual determinations.
Control levels (not shown) are 0.328 + 0.069 and 6.004 +
0.579 for norepinephrine and dopamine respectively.
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reduction from the one hour levels was observed.

Three hours

following DFP, the dopamine levels stopped decreasing and a
3 o percent increase over the two hour levels occurred.

It

is interesting that the lowered dopamine levels in the caudate

-nucleus

at two hours were further reflected in the lowered

norepinephrine levels at three hours.

If one were to compare
/

the time course of the changes in caudate nucleus dopamine
with the time course of the changes in norepinephrine in the
.!!Y-dbrain-diencephalon (cf. Figures 11and12), a striking
similarity can be seen.

As dopamine is particularly present

in the caudate nucleus and norepinephrine in the midbraindiencephalon, one may suggest that the DFP-induced response,
observed with caudate nucleus dopamine and midbrain-diencephalon
norepinephrine, is characteristic of the transmitter most
readily released.

Further studies with quaternary atropine.
Studies using atropine methyl nitrate alone or with,DFP in
midbrain-diencephalon indicate (Figure 13) that ATMN alone
caused a slight elevation in norepinephrine levels compared

'

to levels of norepinephrine in control (no drug) animals: on
the other hand, AT.MN had no.effect on dopamine.

Similar

results were also observed in the case of the caudate nucleus:
norepinephrine and dopamine levels with AT.MN were similar to
.

those levels observed in control rabbits (Figure 14).

From
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LEGEND FOR FIGURE 13

Effect of DFP (2.5 mg/kg, sc); and Atropine methyl nitrate
(2.0 mg/kg, ip), with or without DFP (2.5 mg/kg, sc) on
rnidbrain-diencephalon norepinephrine and dopamine levels.

Values

are expressed as the Mean + the standard error and represent
2-4 individual determinations.
by the horizontal line.

control levels are indicated

Significance was calculated using

Student's test.
• indicates P(0.025 for the difference between lower bargraphs
2 and 3; + indicates P(0.10-0.05 for the difference between
upper bargraphs 2 and 3.
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LEGEND FOR FIGURE 14

Effect of DFP (2.5 mg/kg, sc); and Atropine methyl nitrate
(2.0 mg/kg, ip), with or without DFP (2.5 mg/kg, sc) on
caudate nucleus norepinephrine and dopamine levels.

Values

are expressed as the Mean + the standard error and represent
2-4 individual determinations.
by the horizontal line.

'

Control levels are indicated
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these results it can be concluded that AT.MN block of the DFPinduced elevation of dopamine observed in the midbrain-diencephalon
of rabbits pretreated with JB835-DOPA-ATMN-DFP (2.5 mg/kg)
combination was not due to ATMN itself, but rather to the
combination ATMN-DFP.

Whether JB835 with DOPA influenced

this response is yet to be seen.
ATMN was therefore combined with DFP (2.5 mg/kg) to determine
the validity of the above conclusion.

The results indicate

that in the case of the midbrain-diencephalon, the DFP-induced
decrease of norepinephrine levels were unaffected by AT.MN
treatment which was similar to the observations with AT.MN in
the case of the JB835-DOPA-DFP combination (Figures 10 and 13).
Moreover, ATMN was able to block the DFP-induced elevation of
dopamine (Figure 13), in the absence of the JB835-DOPA pretreatment in confirmation of the earlier findings (Figure 10);
and this fact rules out in addition, any influence of JB835
and DOPA on this response.

ATMN had little, if any, effect

upon dopamine levels in caudate nucleus in response to DFP
(Figure 14) •
It could be then concluded, that in the case of the midbraindiencephalon region the action of the quaternary methylatropine
is responsible for the block in the DFP-induced elevation in
dopamine levels.
The above results with ATMN-DFP combinations suggest that
a peripheral involvement is responsible for the elevation

110
. in dopamine by DFP: on the other hand, the decrease in
:, norepinephrine levels by DFP, which was unaffected by ATMN,
seems to be the result of central actions of DFP.

If a central

release mechanism is the means by which DFP produces the
observed decrease in norepinephrine levels in

~idbrain-dienceph-

el.Qll• it seems unlikely that this effect should concern only
one catecholamine, and dopamine would be expected to be
susceptible to this releasing effect also.

However, any

release in dopamine centrally by DFP would be masked by the
postulated peripheral effect of DFP leading to elevated
central levels of dopamine.

The possibility, in addition, has

not been eliminated that DFP itself may stimulate dopamine
synthesis in the brain and thus produce the elevated levels
of dopamine.
In the presence of the blockade of both the central and
peripheral cholinoceptive sites an elevation in dopamine levels
following this block and a decrease in norepinephrine
levels by DFP would indicate a direct action of DFP itself.
Experiments were therefore carried out to determine DFP's
central actions.

Whether DFP, centrally, induces (1) the direct

release of both norepinephrine' and dopamine, the original
level of the latter being elevated due to DFP's proposed
peripheral influence, or (2)

the release of only norepinephrine

While stimulating dopamine synthesis leading to elevated
levels of dopamine, should be determined from these experiments.
DFP's peripheral influence on dopamine levels is proposed

111

to be the result of increased synthesis of dopamine from DOPA.
Therefore, in the absence of an excess of DOPA, this peripheral
influence would be minimal.

Further, if both the central

and peripheral atropine-sensitive sites were blocked by
atropine, thereby eliminating both the central actions of DFP
(release of norepinephrine), as well as the peripheral
influences of DFP (elevation of dopamine levels), then any
actions of DFP on the rnonoamines would indicate that DFP, itself,
was responsible for the monoarnine responses and that these
responses were not due to Ach acting on the atropine-sensitive
cholinoceptive sites.
Midbrain-diencephalon norepinephrine levels were decreased
by 50 percent in the case of animals pretreated with JB835

prior to the administration of DFP, compared to the norepinephrine
levels in those receiving only JB835 (Figure 15).

Furthermore,

DFP caused a greater than 50 percent increase in dopamine
levels in the midbrain-diencephalon compared to that observed
in "loaded" rabbits given DFP (cf. Figure 2).

In the rabbits

pretreated with JB835, AtSO

(4.0 mg/kg) given prior to DFP
4
blocked the OPP-induced decrease in norepinephrine, the
norepinephrine levels in the atropine-treated animals being
comparable to the norepinephrine levels in JB835-treated
animals (Figure 15).

From these results it is concluded that

the DFP-induced norepinephrine decrease is not a direct action
Of DFP itself, as blockade by atropine would not occur if
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Effect of JB835 (6 mg/kg, ip) with or without DFP (2.5 mg/kg,

~
"~ sc), or Atropine sulfate (4.0 mg/k.g, ip) and DFP (2.5 mg/kg, sc)

v

r

J on midbrain-diencephalon norepinephrine and dopamine levels.
I
~
f Values are expressed as the Mean + the standard error and
f

t

~

~

~

represent 4-6 individual determinations.

Control levels (not

,.'

shown) are 0.336 + 0.035 and 0.257 + 0.045 for norepinephrine

'

and dopamine, respectively.

f.

Significance was calculated using

Student's test.
• indicates P<0.10-0.05 for the difference between both the
upper and lower bargraphs 1 and 2.

'
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pFP'S action was direct.
In addition, the midbrain-diencephalon dopamine levels
in rabbits pretreated with JB835 and given AtSO

(4.0 mg/kg)
4
prior to DFP were not as elevated as in the case of the
. JB835-DFP treated rabbits.

The dopamine levels in the atropine

treated animals were similar to the dopamine levels in the
JB835 treated animals.

As with norepinephrine, the DFP-induced

elevation of dopamine in the midbrain-diencephalon appears
then not to result from direct stimulation of dopamine itself,
but to be induced by the

~pheral

action of DFP.

Results concerning the caudate nucleus were not so clear.
Norepinephrine levels following the various treatments were
similar to those observed in the case of the midbrain-diencephalon.
DFP caused a decrease in norepinephrine levels in JB835
pretreated animals compared to norepinephrine levels of the
rabbits treated with JB835 alone.

In addition, AtSO

(4.0

4
mg/kg} blocked this DFP-induced decrease, the norepinephrine

levels being similar to that observed in the case of the
"loaded" animals given DFP (cf. Figure 1).

However, in the

case of the caudate nucleus, Df P given to JB835-pretreated
rabbits caused not an elevation but a slight decrease in
dopamine levels.

Further, AtSO

given prior to DFP in JB835
4
Pretreated rabbits caused dopamine levels in the caudate
~

nncleus to decrease even more (Figure 16).

l

atropine is unlike that observed in the case of the "loaded"

t

rabbits given AtSO

This response to

(2.0 mg/kg) prior to DFP (cf. Figure 7),
4
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LEGEND FOR FIGURE 16

Effect of JB835 (6 mg/kg, ip) with or without DFP (2.5 mg/kg,
sc), or Atropine sulfate (4.0 mg/kg, ip) and DFP (2.5 mg/kg, sc)
on caudate nucleus norepinephrine and dopamine levels.

Values

are expressed as the Mean + the standard error and represent
4-5 individual determinations.

Control levels (not shown) are

0.328 + 0.069 and 6.004 + 0.579 for norepinephrine and dopamine,
respectively.

Significance was calculated using Student's test.

• indicated P{0.10-0.05 for the difference between bargraphs
1 and 2.

'
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where a slight block of the decrease in dopamine occurred.

These

;observed differences may be due to the difference in the
pretreatments.

!Pe effects of DFP on catecholamines of brain-parts.
Thus far all experiments have been carried out with regard
to midbrain-diencephalon and caudate nucleus.

It has been

demonstrated that DFP given to animals pretreated with JB835
and DOPA caused a significant decrease in norepinephrine levels
in the midbrain-diencephalon, while at the same time significantly
elevated dopamine levels in this area.

Atropine sulfate

given prior to the DFP in JB835-DOPA pretreated animals blocked
both the norepinephrine decrease and the dopamine increase.
Atropine methyl nitrate given prior to DFP in animals pretreated with JB835 and DOPA blo.cked only the dopamine elevation,
suggestive of peripheral involvement.
l

These responses were

most pronounced in the midbrain-diencephalon area compared to
those obtained in the case of the caudate nucleus.

Therefore,

additional experiments were carried out to determine whether.
specific areas within the midbrain-diencephalon region, i.e.

'
midbrain, thalamus, and hypothalamus,
could all exhibit the
DFP responses, namely a decrease in norepinephrine levels and
an increase in dopamine levels.

An additional area, the

hippo~

campus, was also selected to demonstrate DFP's effects on a

I

~.

non-midbrain-diencephalon area.

118
Mean norepinephrine levels in the thalamus, the hypothalamus,
:the midbrain, and the hippocampus were decreased by DFP (2.5
mgfkg) in rabbits pretreated with JB835 and DOPA when compared
to norepinephrine levels in the animals receiving only JB835
and DOPA.

Forty two, 13, 25, and 16 percent decreases in

, norepinephrine were observed in the thalamus, hypothalamus,
midbrain, and in the hippocampus, respectively (Figure 17).

"

Thus, the responise to DFP was not restricted to any one specific
area.

The fact that this response to DFP was non-localized

.

might have been predicted based on the reported presence of
, both cholinoceptive and adrenergic neurons within these brain
areas.
Addition of ATMN prior to DFP in rabbits pretreated with
' JB835 and DOPA had no effect upon DFP's ability to decrease
norepinephrine levels.

In both the thalamus and mid.brain, the

levels of norepinephrine following the JB835-DOPA-ATMN-DFP

t

r

combination were nearly identical with those in the case of

l

rabbits treated with the JB835-DOPA-DFP combination.

In the

hypothalamus and hippocampus ATMN given prior to DFP in JB835DOPA pretreated rabbits 9aused,a further reduction in norepinephrine levels (25 and 21 percent, respectively} compared to
the norepinephrine levels following JB835-DOPA-DFP combinations.
The order of responses observed in these four brain areas

l
!

is identical with that of the norepinephrine responses in the
Midbrain-diencephalon (Figure 10).
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LEGEND FOR FIGURE 17

Effect of JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip), with
or without DFP (2.5 mg/kg, sc), or Atropine methyl nitrate
(2.0 mg/kg, ip) and DFP (2.5 mg/kg, sc) on norepinephrine levels
in the thalamus, the hypothalamus, the midbrain, -and the
hippocampus.

Values are expressed as the Mean + the standard

error and represent 3-4 individual determinations.

Control

levels for each brain part are indicated by the horizontal line.
Stati.stical significance was calculated using Student's test.

+ indicates P<0.05 for the difference between bargraphs 1 and
2 in the thalamus; • indicates P(0.10-0.05 for the difference
between bargraphs 1 and 2 in the rnidbrain.
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DFP given to animals pretreated with JB835 and DOPA caused
an elevation of dopamine levels in the thalamus, the hypothalamus, the midbrain, and the hippocampus compared to
dopamine levels of the animals treated with JB835 and DOPA
' (Figure 18).

A 35, 311, 57, and 6 percent increase was

observed in the case of the thalamus, hypothalamus, midbrain,
and hippocampus respectively; the effects recorded in the
" case of the hypothalamus and midbrain were statistically
significant.

As in the case of norepinephrine, the DFP-induced

elevation in dopamine levels within these four brain areas was
of identical order with that of the dopamine responses due
to DFP in the midbrain-di.encephalon (Figure 10).

Moreover, the

DFP-induced dopamine elevation occurred in the midbraindiencephalon, as well as in the non-midbrain-diencephalon
area, indicating a non-localized effect of DFP.
The administration of ATMN prior to DFP in rabbits pretreated
with JB835 and DOPA caused a block in the elevation of dopamine
by DFP in all four brain areas (Figure 18).

In the thalamus,

a significant 87 percent reduction in dopamine levels occurred
compared to the dopamine

level~

in the case of the rabbits

treated with JB835-DOPA-DFP combination; in the hypothalamus,
. midbrain, and hippocampus, decreases of 55, a significant 58,

!

l

and 34 percent, respectively, were noted.

Again, the degree

i

~

t

Of the blocking effect of ATMN on the DFP-induced elevation in
dopamine levels in these four brain areas was identical with
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LEGEND FOR FIGURE 18

Effect of JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), with
or without DFP (2.5 mg/kg, sc), or Atropine methyl nitrate {2.0
mg/kg, ip) and DFP (2.5 mg/kg, sc) on dopamine levels in the
thalamus, the hypothalamus, the mid.brain, and the hippocampus.
Values are expressed as the Mean + the standard error and represent
3-4 individual determinations.
part are indicated by the

Control levels for each brain

horizon~al

line.

Statistical

significance was calculated using Student's test.
o indicates P<0.01 for the difference between bargraphs '2 and
3 in the thalamus; e indicates P(0.10-0.05 for the difference
between bargraphs 1 and 2 in the hypothalamus; + and • indicates
P(0.05 and P(0.025 for the differences between bargraphs 1 and
2, and 2 and 3, respectively, ' in the mid.brain.

'

,'
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tnat observed in the case of the midbrain-diencephalon (cf.
Figure 10) .
These and earlier data presented strongly suggest that the
blocking action of ATMN on the DFP-induced elevation in
dopamine levels observed in the midbrain-diencephalon occurs
at the peripheral cholinoceptive sites otherwise stimulated
by the DFP-induced elevation in acetylcholine.

The effects of the intraventricular administration of DFP.
Data thus far obtained suggest a central, as well as a
peripheral action of DFP.

However, it is difficult to separate

DFP's central releasing effect from its peripheral dopamine
elevating effect.

Using ATMN, it was possible to block the

peripheral elevating effect of PFP, but it could not be
determined whether DFP, in addition to this action, was
influencing the central amines through stimulation of nonatropine sensitive sites.

If DFP were administered via the

intraventricular rather than the subcutaneous route, the
central actions of DFP could be more easily observed, being
"divorced" under these circumstances from the peripheral
influences.

of

Previous investigators have used intraventricular injection
of drugs, i.e. acetylcholine, carbachol, norepinephrine, which
have both peripheral and central actions, to separate the central
from the peripheral responses to these agents (Feldberg, 1963;

125
Feld.berg, 1958; Grossman, 1968: and Stein, 1970).

The majority

of these studies were investigating behavorial responses
to central stimulation by the various drugs, in an attempt

·.:
!

to identify the brain areas involved in producing these responses
and, in addition, the types of neurons, i.e. cholinergic or
adrenergic, involved.
Injection of lOOµg of DFP into the lateral ventricle of
cat was carried out by Feldberg {1958).
stages, which overlapped, were reported.

Three symptomological
The first stage

had consisted of severe itching, wiping of the face and forelegs,
and vigorous licking and chewing motion of the jaws.

Itching

is a characteristic sign of anticholinesterase action, probably
resulting from inhibition of cholinesterase and subsequent
accumulation of acetylcholine in the tissues lining the
ventricular walls.

During the second stage, increased tone

and tremor of skeletal muscle occurred.

The first two stages

were relatively short in appearance while the third stage lasted
longer.

The third stage was characterized by an alteration of

awareness and the development of stupor and catatonia.

In

this condition, the cats coulq be placed in abnormal positions
which they retained for some minutes.

Similar signs of

catatonia were observed when eserine or large doses of acetylcholine were injected intraventricularly.
Rabbits given 200pg of DFP via the intraventricular route
in the present study exhibited similar signs.

The initial
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excitement stage was characterized by either clockwise or
counter-clockwise spinning movements; each animal spinning
in only one direction.

The rabbits subsequently developed

a_ tonic type of kicking, and tremors.

The last stage, begin-

ning about 10 minutes after the injection, was characterized
by a chewing jaw motion while the animals were lying in a

resting position.
to side.

Frequently the animals would rock from side

In a few cases the rabbits were up on all four legs

in a catatonic-like stance moving their head from side to side.
This stance lasted, however, only for 5 or 10 minutes.

Pinpoint

pupils, severe salivation, and foreleg muscle fasciculations
were not as apparent as they were when DFP was given by the
subcutaneous route.

These behavorial responses in rabbits to intra-

ventricular injection of DFP were identical in many respects to
those responses observed in cats treated similarly.
In the initial experiments, the procedures of which are
described in the Methods, the rabbits were anesthetized with
sodium pentoba.rbital.

The results obtained (Figures 19 and 20)

with regard to the midbrain-diencephalon and caudate nucleus
in the rabbits given JB835

an~DOPA

and not DFP, indicate

that the pentobarbital was interfering with the normal uptake
and release mechanisms for both norepinephrine and dopamine.
As can readily be seen, the norepinephrine levels in both brain
areas in the case of the sham controls (given JB835-DOPA-Saline

.

i
:

combination) were considerably more elevated than the norepinephrine
levels in animals similarly treated but not anesthetized (Tables
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LEGEND FOR FIGURE 19

Effect of intraventricular injection of DFP (200µg) or Saline
on norepinephrine and dopamine levels in rabbit midbraindiencephalon with and without pentobarbital anesthesia following
pretreatment with JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip),
or JB835-DOPA-and ATMN (2.0 mg/kg, ip).

Values are expressed

as the Mean + the standard error and represent 3-4 individual
determinations.

Statistical significance was calculated using

Student's test.

o indicates P(0.025 for the difference between bargraphs 1 and

2;

~

indicated

1 and 3.

P~0.005

for the difference between bargraphs
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LEGEND FOR FIGURE 20

Effect of intraventricular injection of DFP (200pg) or
Saline on norepinephrine and dopamine levels in rabbit caudate
nucleus with and without pentobarbital anesthesia following
pretreatment with JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip),
or JB835-DOPA- and ATMN (2.0 mg/kg, ip).

Values are expressed

as the Mean + the standard error and represent 3-4 individual
determinations.

Statistical significance was calculated using

Student's test.

Statistical significance (P(O.OS)was found

for the difference between the upper bargraphs 2 and 3.

'
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1 and 2).

Similar results were observed in the case of the

dopamine levels.

Maynert and Levi (1964) reported that sodium

pentobarbital prevented the morphine-induced decline in brainstem

norepinephrine in cats, which led to elevated norepinephrine

levels.

It appeared that in the case of our intraventricular

studies, pentobarbital acted in a similar manner.

Therefore,

additional experiments were performed using unanesthetized
rabbits.
DFP (200pg) injected into the left lateral ventricle in
rabbits pretreated with;JB835 and DOPA, caused a marked 33
percent decline in norepinephrine levels in the midbraindiencephalon (Figure 19) relative to the norepinephrine levels
observed in the case of the rabbits treated with JB835-DOPASaline combinations (sham controls).

Although the intra-

ventricular dose of DFP differed from that previously given
s.c.

(2.5 mg/kg), the response induced by DFP was identical,

indicating that the releasing action of DFP was centrally
mediated.

A similar decrease in norepinephrine levels was

observed in the pentobarbital anesthesized rabbits, although
the overall levels of norepinephrine were higher.

AT.MN given

prior to the intraventricular administration of DFP to rabbits
pretreated with JB835 and DOPA had no effect on the DFP-induced
decrease in norepinephrine levels observed in the case of the
rabbits treated with JB835-DOPA-DFP (intraventricular) combinations.
This inability of AT.MN to block the decrease in norepinephrine
produced by DFP via the intraventricular route is identical with
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the effects observed of ATMN on the DFP-induced decrease in
norepinephrine observed in the midbrain-diencephalon when DFP
was given s.c.

(cf. Figure 10).

ATMN was incapable of blocking

the actions of DFP on norepinephrine levels, whether DFP was
administered via the s.c. or intraventricular routes.
Dopamine levels in the midbrain-diencephalon of non-anesthetized
rabbits, pretreated with JB835 and DOPA were not significantly
different from the dopamine levels in the case of the rabbits
given JB835-DOPA-Saline combinations; the dopamine levels
were slightly but not significantly higher (Figure 19)
following DFP.

In similarly treated rabbits anethetized with

pentobarbital, a marked decrease in dopamine levels by DFP
was observed; however, it should be remembered that the dopamine
levels in anesthetized rabbits were higher than those observed
in unanesthetized rabbits.
The lack of elevated dopamine levels induced by DFP via the
intraventricular route, as opposed to the significant elevation
in dopamine levels induced by DFP via the subcutaneous route,
seems to indicate that the-------latter effect is due to the peripheral,
not central, action of DFP.

'

Further support for this conclusion was obtained .in the
experiments in which ATMN was given prior to the intraventricular
administration of DFP in rabbits pretreated with JB835 and DOPA.
The levels of dopamine in the midbrain-diencephalon did not
differ significantly from the levels of dopamine in either the
rabbits given the JB835-DOPA-Saline combination, or the JB835-
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pOPA-DFP (intraventricular) combination.

Thus, DFP administered

via the intraventricular route had no effect upon the dopamine
1evels in either JB835, DOPA pretreated animals or in those
receiving, in addition, AT.MN.

These results were in sharp

opposition to those observed in the experiments in which DFP
was administered via the subcutaneous route; they firmly
support the notion of the peripheral action of DFP involved
in producing the elevation in dopamine levels within the
midbrain-diencephalon.
As expected, in the caudate nucleus, the response to the
intraventricular injection of DFP (200µg) was not well defined.
This was typical of the caudate nucleus as the lack of conformity
with those results obtained in the case of the midbraindiencephalon was observed in the earlier experiments.

Norepinephrine

levels, in unanesthetized rabbits pretreated with JB835 and DOPA
given DFP (200pg) intraventricularly, were not different from
norepinephrine levels in animals treated with JB835-DOPA-Saline
combination (Figure 20).

In animals treated similarly, but

not anesthetized with pentobarbital, there was a 29 percent
though not significant, decrease in the norepinephrine levels

'

in the DFP treated animals compared to those without DFP.
AT.MN given to unanesthetized animals pretreated with JB835 and
DOPA followed by DFP intraventricularly produced a significant
(P~0.05)

38 percent decrease in norepinephrine levels compared

to the norepinephrine levels in the case of the animals treated
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with the JB835-DOPA-DFP (intraventricular) combination.

f.
~

Dopamine

1evels in caudate nucleus were n?t significantly different
in rabbits treated with : JB835-DOPA-Saline combination; JB835DOPA-DFP (intraventricular) combination; or JB835-DOPA-ATMNDFP (intraventricular) combination.

However, there was a 15

percent (not significant) increase in dopamine levels observed
in the case of the rabbits treated with JB835-DOPA-DFP combination
compared with the animals receiving JB835-DOPA-Saline combination
(Figure 20).

A similar increase in dopamine levels was observed

in anesthetized rabbits treated with JB835-DOPA-DFP (intraventricular) combination.

The effect of DFP on cholinesterases and on acetylcholine.
The assumption that because DFP is a potent anticholinesterase
the rabbit brain cholinesterases will be inhibited following
DFP administration is not a valid assumption without direct
evidence of such inhibition.

It was for this purpose that

experiments, measuring the percent of cholinesterase (total
acetylcholinesterase~and 25 percent of butrylcholinesterase)

inhibition produced by DFP (2.5 mg/kg) in the thalamus, the

' the caudate nucleus were
hypothalamus, the mid.brain, and
performed.

Rabbits were treated, as described in the Methods,

with the following combinations:

JB835-DOPA; JB835-DOPA-DFP:

JB835-DOPA-AtSO -DFP; and a no-drug control group was also

'
employed.

4

Their cholinesterase activity was measured in terms

of the Rate of Hydrolysis (Moles of substrate hydrolyzed/ minute
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/ gram of tissue) of cholinesterase.
Cholinesterase activity in the thalamus, the hypothalamus,
the mid.brain, and the caudate nucleus of rabbits treated
with JB835 and DOPA was almost identical (not significantly
different) to the cholinesterase activity in control (no drug)
animals (Table 3).

These results indicate that JB835 and

DOPA are without effect upon the activity of cholinesterase
in these four brain areas.

The data further confirms the

reported findings that the cholinesterase activity is highest

in the caudate nucleus and mesencephalon (mid.brain) regions
of the brain (Votava, 1967 and Karczmar, 1967), the mean rate

-4
being 0.22 X 10

-4
for the caudate nucleus and 0.12 X 10

for

-4
the mid.brain as compared to 0.07 X 10

for the thalamus

-4
and 0.10 X 10

for the hypothalamus (for S.E. 's cf. Table 3).

Using the cholinesterase activity in the rabbits treated
with JB835 and DOPA (sham controls) to represent zero percent
inhibition it was found that the addition of DFP (2.5 mg/kg)
to rabbits pretreated with JB835 and DOPA produced a 96.30
percent inhibition of cholinesterase activity, or greater,
in the caudate nucleus, the mid.brain, the thalamus, and in the

'

hypothalamus (Figures 21 and 22).
when AtSO

Similar results were obtained

was given prior to DFP in rabbits pretreated with
4

JB835 and DOPA, the percent of brain cholinesterase inhibition
being 97.50 or greater in the four brain areas.

Thus the

administration of DFP (2.5 mg/kg) did produce nearly 100
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TABLE 3

CHOLINESTERASE ACTIVITY IN RABBIT BRAIN PARTS

Mean Rate* of Substrate Hydrolysis
+ Standard Error

Midbrain

Caudate N.

Thalamus

Hypothalamus

+
control (no drug)

0.22+ 0.01

0.12+ 0.01 0.07+ 0.00 0.10+ 0.02

JB835-DOPA

0.22+ 0.01

0.13+ 0.01 0.06+ 0.02 0.08+ 0.02

JB835-DOPA-DFP

0.00+ 0.00

0.00+ 0.00 0.00+ o.oo 0.00+ 0.00

JB835-DOPA-AtSO -DFP
4

0.00+ 0.00

0.00+ 0.00 0.00+ 0.00 0.00+ 0.00

-4 '
and represent the mean of two determinations.

+

All values are X 10

*

Rate= Moles of substrate hydrolyzed/minute/gm. tissue.

Doses used:

JB835, 6 mg/kg, ip; DOPA, 50 mg/kg, ip; DFP, 2.5

mg/kg, sc; AtSO , 2.0 mgjkg, ip.
4
No statistically significant difference was found between the
cholinesterase activity of the control and JB835-DOPA combinations
in any of the four brain areas.

Statistical significance was

'
found between the JB835-DOPA combination
and each of the DFP
containing combinations; the significance being in the caudate
nucleus and midbrain P(0.005; in the thalamus P(0.10-0.05; and
in the hypothalamus P<O;o5.
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LEGEND FOR FIGURE 21

Percent of cholinesterase inhibition by DFP (2.5 mg/kg, sc)
in the caudate nucleus and midbrain of rabbit following
pretreatment with JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip),
or JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip).

JB835-

DOPA combination represents zero percent inhibition of cholinesterase
activity.

Values represent the mean of two assays.

significance was calculated using Student's test.

Statistical
P(0.005

significance was found for the difference between bargraphs
1 and 2, and 1 and 3 for the caudate nucleus and the midbrain.
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LEGEND FOR FIGURE 22

Percent of cholinesterase inhibition by DFP (2.5 mg/kg, sc)
in the thalamus and the hypothalamus of rabbit following
pretreatment with JB835 (6 mg/kg, ip) and DOPA (SO mg/kg, ip),
or JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip).

JB835-

DOPA combination represents zero percent inhibition of cholinesterase
activity.

Values represent the mean of two assays.

significance was calculated using Student's test.

Statistical
P~0.10-

0.05 was found for the difference between bargraphs 1 and 2,
and 1 and 3 for thalamus;

P<0.05 was found for the difference

between bargraphs 1 and 2, and 1 and 3 for the hypothalamus.

'
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. percent cholinesterase inhibition in rabbits pretreated with
JB835 and DOPA, or with JB835, DOPA, and AtSO • It is also
4
evident that AtSO does not interfere with DFP's ability to
4
inhibit cholinesterase.
While the above data suggest that DFP should have elevated
acetylcholine levels, as cholinesterases are the enzymes
responsible for the hydrolysis of the latter, it was still
necessary to demonstrate directly that indeed DFP (2.5 mg/kg,
sc) elevated the levels of acetylcholine in the caudate nucleus,
midbrain, thalamus, and hypothalamus in rabbit.

Using bioassay

techniques, acetylcholine levels were assayed in two samples
each of the four brain areas for each drug combination.

There

was little difference between acetylcholine levels of the
r.

~

rabbits receiving the JB835 and DOPA treatment as compared to
the levels found in the control rabbits in the case of the
caudate nucleus, midbrain, thalamus, or hypothalamus (Table
4).

Taking the acetylcholine levels in the caudate nucleus,

midbrain, thalamus, and hypothalamus of control (no drug)
rabbits as representing 100 percent of acetylcholine it was
found that, of the four brain'areas from the animals treated
with JB835 and DOPA, the midbrain exhibited the greatest
deviation from its respective control acetylcholine level1
this deviation was only 11 percent (Figures.23-26).

It was,

in addition, found that neither JB835 nor DOPA had any
·~ignificant

effect, compared to the control rabbits, upon
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TABLE 4

EFFECT OF DRUGS ON ACETYLCHOLINE LEVELS IN RABBIT BRAIN PARTS

Acetylcholine ug/gm.

Q_rugs

caudate N.

Midbrain

Thalamus

Hypothalamus

control ·{no drugs)

2.02
2.19

1.35
1.21

1.35
1.53

1.06
1.00

+

NS
1.82
1.38

1.40
1.43

1.88
1.93

JB835-DOPA

NS

NS

NS

0

0

•

. 1.01
1.03

DFP

5.59
4.36

4. 39
5.76

4.08
4.70

JB835-DOPA-DFP

5.00
6.30

4.78
4.08

3.62
3.47

3.25
3.50

JB835-DOPA-AtSO -DFP
4

5.89
4.80

3.67
3.56

2.81
3.17

2.68
3.01

JB835-DOPA-ATMN-DFP

4.73
4.28

4.39
5.10

3.96
3.07

3.49
3.46

Values represent individual bioassays.

Doses used:

4.13
4.64

JB835, 6

mg/kg, ip; DOPA, 50 mg/kg, ip; DFP, 2.5 mg/kg, sc; AtSO , 2.0
4
mg/kg, ip; ATMN, 2.0 mg/kg, ip. Statistical significance
was calculated using Student's' test.·

+ indicates P<0.05 for the difference between the two groups;
o indicates P(0.025 for the difference between the two groups;
• indicates P(0.005 for the difference between the two groups.
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LEGEND FOR FIGURE 23

Percent of acetylcholine increase over control (no drug)
acetylcholine levels in the rabbit caudate nucleus followhg
JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg,
sc) with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip},
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip), or JB835DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip).

Percent

increases are determined from the mean of two individual
bioassays + the standard error.
of 100 percent acetylcholine.

Control levels are representive
Statistical significance was

calculated using Student's test.
The difference between the mean values of bargraphs 2 and 3
was found to be significant (P(0.05).
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LEGEND FOR FIGURE 24

Percent increase of acetylcholine over control (no drug)
acetylcholine levels in the rabbit midbrain following JB835
(6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg, sc)
with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip),
JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip), or
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip).

Percent

increases are determined from the mean of two individual
bioassays + the standard error.
of 100 percent acetylcholine.

Control levels are representive
Statistical significance was

calculated using Student's test.

The difference between the

mean values of bargraphs 2 and 3 was found to be significant
(P(0.025).
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LEGEND FOR FIGURE 25

Percent increase of acetylcholine over control (no drug)
acetylcholine levels in the rabbit thalamus following JB835
(6 mg/kg, ip) and DOPA (SO mg/kg, ip), or DFP (2.5 mg/kg,sc)
with or without JB835 (6 mg/kg, ip) and DOPA (50 mg/kg, ip)_
JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg,ip}, or
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip). Percent
increases are determined from the mean of two individual
bioassays + the standard· error.
of 100 percent acetylcholine.

Control levels are representive
Statistical significance was

calculated using Student's test.

The difference between the

mean values of bargraphs 2 and 3 was found to be significant
(P(0.025).
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LEGEND FOR FIGURE 26

Percent increase of acetylcholine over control (no drug)
acetylcholine levels in the rabbit hypothalamus following JB835
(6 mg/kg, ip) and DOPA (50 mg/kg, ip), or DFP (2.5 mg/kg,sc)
with or without JB835 (6

m~/kg,

ip) and DOPA (50 mg/kg, ip),

JB835-DOPA- and Atropine methyl nitrate (2.0 mg/kg, ip), or
JB835-DOPA- and Atropine sulfate (2.0 mg/kg, ip).

Percent

increases are determined from the mean of two individual
bioassays + the standard error.
of 100 percent acetylcholine.

Control levels are representive
Statistical significance was

calculated using Student's test.

The difference between the

mean values of bargraphs 2 and 3 was found to be significant
(P(0.005).
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acetylcholine levels in any of the four brain areas.
DFP (2.5 mg/kg} alone produced increases in acetylcholine
content compared to its effect in the animals pretreated with
the JB835-DOPA combination.

The percent increases, all of

which were significant, due to DFP alone were:

297, 205,

330, and 136 in the midbrain, the thalamus, the hypothalamus,
and the caudate nucleus, respectively, over the acetylcholine
levels in identical areas of the JB835-DOPA treated rabbits.
DFP given to rabbits pretreated with JB835 and DOPA caused
an elevation in the acetylcholine levels over control acetylcholine levels by 168, 246, 146, and 228 percent in the caudate
nucleus, the mid.brain, the thalamus, and the hypothalamus,
respectively.

When AT.MN was given prior to DFP to JB835 and

DOPA pretreated animals acetylcholine levels elevated by the
DFP as compared to control levels were:

114, 271, 144, and

238 percent in the caudate nucleus, midbrain, thalamus, and in
the hypothalamus, respectively.
It. is evident that DFP, whether alone or following pretreatment with JB835 and DOPA or JB835, DOPA, and AT.MN, produced
marked elevations in acetylcholine levels in these four brain

•

areas in rabbit: this then relates well with the demonstration
of cholinesterase inhibition produced by DFP in these four
areas (cf. Figures 21 and 22).
A special comment is required with regard to the last drug
combination: in this case, atropine sulfate, given prior to
DFP in rabbits pretreated with JB835 and DOPA, was observed

l
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to interfere somewhat with the elevation of acetylcholine
1evels by DFP.

Although this interference was not found to

be statistically significant, a trend was evident.

In the

midbrain, thalamus, and hypothalamus acetylcholine levels in
atropine sulfate treated animals were lower following DFP
than all other DFP containing drug combinations (Figures 24-

26).

The only brain area where this effect was was not observed

was the caudate nucleus, where the acetylcholine levels of
the atropine sulfate treated animals were were approximately the
same as the other drug groups containing DFP (Figure 23).
The observed lessening of

DFP~induced

levels was, however, anticipated.

elevation of acetylcholine

Mitchell (1963}, Szerb (1964),

and Polak and Meeuws (1966) demonstrated that atropine sulfate
enhanced the release of acetylcholine from the cerebral cortex
of the cat, rabbit, sheep, and rat.

Similar results were

also observed in rats by Hingtgen and Aprison (1970).

Thus,

the observation that in the presence of AtSO , acetylcholine
4
levels following DFP were less than those observed in animals
not pretreated with AtSO , seem reasonable.
It would seem that
4
caused
a
lowering
of
acetylcholine levels through
AtSO
I(
4
release, and subsequent degradation of acetylcholine by
cholinesterase, prior to the administration of DFP.

Thus,

with an initial lowered level of acetylcholine, the elevation
of acetylcholine levels caused by DFP was less in those drug
combinations where the acetylcholine levels were not initially
lowered by atropine.

It should also be pointed out that this
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effect was not observed following DFP in animals pretreated
with drug combinations which included ATMN.
Regardless of the individual variations within each brain
area, all drug combinations containing DFP (2.5 mg/kg) showed
acetylcholine levels which were elevated a minimum of 100
percent over control acetylcholine levels.

Altogether, we

, could demonstrate that DFP at a dose of 2.5 mg/kg, s.c.
adequately inhibited brain cholinesterase in all four brain
areas (Table 3), causing marked elevation in the acetylcholine
levels within these areas (Table 4).
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DISCUSSION

The concept of cholinergic-adrenergic coupling is not by
any means novel.

Burn and Rand in 1959 had proposed for the

peripheral nervous system, a neural mechanism by which acetylcholine was able to cause the release of norepinephrine from
sympathetic nerve terminals.

Koelle (1963) modified this

concept to allow for acetylcholine, having been released
from a nerve terminal, to act back upon that nerve terminal
from which it was released, to cause a "percussive" release
of norepinephrine.
Considerable evidence has been presented over the years
which seems to support these concepts.

Only recently, however,

has attention been focused upon the possibility of a cholinergicadrenergic mechanism existing in the central nervous system.
Both electrophysiological and neurochemical evidence
obtained by Van Meter (1969) and Van Meter and Karczmar (1970)
suggested an interplay between the central neurotransmitters,
acetylcholine and norepinephr\pe, in the anticholinesterase
(eserine) produced blockade of EEG recruitment.
~n

Specifically,

rabbits whose norepinephrine levels had been depleted

by aC.MPT, and related drugs, eserine administration was unable
to produce blockade of the EEG recruitment.

However, following

replenishment of the norepinephrine stores with DOPA administration,
'

l

the ability of eserine to block EEG recruitment was restored.
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Additional evidence of Karczmar and Longo (1970) and Karczmar
et al.

(1971) demonstrated a similar relationship in rabbits

in the case of the paradoxical sleep phenomena.
More recently, Philippu (1970) has provided evidence which
indicates that acetylcholine does, in fact, cause the release
of norepinephrine from cerebral cortex in cat, provided
calcium is present.
Although these findings indicate the possibility for the
existence of a central cholinergic-adrenergic link, they do
not provide comprehensive evidence on the transmitter systems
involved, and the results dealing with acetylcholine,
norepinephrine, and dopamine, as well as cholinesterases, i.e.
acetyl-, butrylcholinesterase, etc., remain incomplete.
The present studies were therefore undertaken to provide
evidence as to the central effects produced by the anticholineste rase, DFP.

The questions to be answered relate to:

(1)

the effect of DFP upon the activity of cholinesterase;

(2)

the subsequent effects upon the levels of acetylcholine due

to cholinesterase inhibition by DFP; and (3)

the effect of DFP

and/or acetylcholine upon the norepinephrine and dopamine
levels.

In addition, these findings would hopefully provide

a base from which an understanding of the mechanisms involved
in central cholinergic-adrenergic coµpling could evolve.
Measurement of the cholinesterase levels in the midbrain,
the thalamus, the hypothalamus, and the caudate nucleus confirmed

r
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that nearly 100 percent inhibition of cholinesterase activity
was obtained using the 2.5 mg/kg, sc, dose of DFP, with or
without pretreatment with JB835 and DOPA.

Moreover, results

on the activity of cholinesterase in control rabbits confirms
previous findings (Karczmar, 1967, and Votava, 1967) that
cholinesterase activity is highest within the caudate nucleus
and the mesencephalon {midbrain) areas in cat, rat, mouse, and
rabbit.
With the marked inhibition of cholinesterase activity,
acetylcholine levels were found to be elevated by this dose
of DFP.

In the midbrain, the thalamus, the hypothalamus, and

the caudate nucleus, DFP caused a minimum of 100 percent increase
in the levels of acetylcholine.

In no case did the JB835 and

DOPA pretreatment cause significant differences in the effect of
DFP on either the cholinesterase activity or on levels of acetylcholine.

As such, the role of JB835 and DOPA in these experiments

was restricted to elevating the levels of norepinephrine and
dopamine which allowed the DFP-induced responses to be more
readily observed.
Of possibly greater significance was the lack of effect on

'

the acetylcholine levels in the thalamus, the hypothalamus, the
midbrain, and the caudate nucleus·, of either norepinephrine or .
dopamine, levels of which were elevated by the administration of
the JB835-DOPA combination.

The postulation of Burn and Ran~,

as well as that of Koelle, provided for the action of
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acetylcholine upon the sympathetic nerve terminals to cause
the release of norepinephrine.

As such, their proposal

provided for cholinergic (acetylcholine) actions upon the
sympathetic adrenergic (norepinephrine) nerve terminals.

However,

the possibility of adrenergic actions upon cholinergic nerve
terminals was not considered in either the Burn and Rand or
Koelle proposals.

Until now there has been no reported

evidence concerning the possibility of an adrenergic-cholinergic
link.

In the present experiments it was demonstrated in

rabbits that norepinephrine and dopamine in a "loaded" state (that
is after the monoamine levels were elevated by JB835-DOPA
pretreatment) did not cause significant changes in the levels
of acetylcholine in the midbrain, the thalamus, the hypothalamus,
or the caudate nucleus.

These findings are highly significant

and suggest that the possible mechanism of adrenergic-cholinergic
coupling does not exist in these rabbit brain areas.
It should be pointed out, however, that the above conclusion
was based upon data obtained from animals whose levels of
monoamines were in a "loaded" state, but whose acetylcholine
levels were not.

The possibility should not be excluded that

'

monoamines can exert some type of influence other than a
coupling phenomena, i.e. competition of the transmitters for
available storage sites, upon the levels of acetylcholine.
Evidence obtained from animals given DFP alone or JB835-DOPADFP indicate that in the latter case, the levels of acetylcholine

l
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were lower than in the case of the former in the thalamus,
the hypothalamus, and the midbrain.

Similar responses were

observed in the case of rabbits pretreated with JB835-DOPAATMN- and given DFP compared to those given DFP alone.

Although

these differences were not significant, their trend suggest
the possibility of monoamine influence upon acetylcholine
levels when both transmitters are in the "loaded" state.
The questions that arise are concerned with the mechanisms
involved in the acetylcholine-catecholamines coupling and
particularly in the differential effects on dopamine and on
norepinephrine.
The present findings demonstrate that in rabbits, DFP given
systemically, induc:es · significant increments of dopamine
levels and significant decrements of norepinephrine levels in
the midbrain-diencephalon and to some extent, the caudate nucleus
regions.

These changes, however, could be noted only after

the levels of these monoamines were increased by appropriate
pharmacological maneuvers, as DFP did not affect the monoamines
without prior JB835 and/or DOPA pretreatment.

This finding

suggest that the effects of DFi on the monoamines are best
observed under optimal conditions for their neuronal synthesis
and storage.

Conversely, in the studies on amine uptake and

release the results were best observed in animals depleted
of monoamines by reserpinization (Anden et al., 1964).

Of

course, DFP may have induced less pronounced changes under
less favorable conditions as well, which escaped detection
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by our methods; they may be however revealed by more sensitive
techniques, as well as, be reflected more readily in the
change in the monoamine turnover values, which were not studied
at present.
One would expect that acetylcholine would exert a similar
effect on both the monoamines.

However, the rate of synthesis

of dopamine is much higher than that of norepinephrine {Weiner,
1970), while perhaps the opposite may be true with regard
to their rates of release and elimination.

It may be then

speculated that these two mechanisms may favor increased
synthesis and storage of dopamine and increased dissipation
of norepinephrine in the presence of accumulated acetylcholine.
It should be pointed out that the acetylcholine-induced
increase in dopamine in "loaded" rabbits was conspicuous in the
case of the diencephalon-mesencephalon area, and inconsistent
and much less pronounced in that of the caudate nucleus.

This

may be related in some way to the high dopamine level in the
latter compared to the former {cf. Tables 1 and 2).

It might

be considered that since the highest levels of dopamine in the
brain are found in the caudate nucleus, a much greater

•

stimulatory effect upon the dopamine levels is needed by
acetylcholine to produce a significant dopamine increase,
the levels of which are already high, compared to the amount
of stimulation needed by acetylcholine to produce a significant
dopamine increase in the case of the midbrain-diencephalon, whose

r
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levels of dopamine are much lower.

Speculatively, it is also

possible that acetylcholine activation embraces only norepinephrinerich neurons in the caudate, and both norepinephrine- and
dopamine-rich neurons in the midbrain and related areas.
It is difficult to explain why the responses observed in the
case of the midbrain-diencephalon are not always observed in
the case of the caudate nucleus.

The above suggestion regarding

the dopamine levels may serve to provide a possible explanation as to the lack of response to acetylcholine by this
transmitter in the caudate.

With regard to norepinephrine,

the lack of response to acetylcholine by this amine could be
due to the fact that norepinephrine levels in the caudate
nucleus are extremely low, if not almost undetectable.

It is

possible that of the two monoamines in the caudate, dopamine
serves as the actual transmitter, while norepinephrine serves
only as a metabolic biproduct formed in the degradation of
dopamine by

dopamine-~-hydroxylase.

Still another possibility

could be that the cholinergic and adrenergic neurons within
the caudate nucleus might not be compatible for a cholinergicadrenergic coupling, i.e. the

~reposed

acetylcholine stimual.ted

interneuron is not present in the caudate nucleus.
Clarification should be made as to the mechanism by which
DFP administration produces the elevation in dopamine levels
and the decrease in norepinephrine levels in the midbraindiencephalon, and to a lesser extent in the caudate nucleus.

;

l
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There are three possible explanations of DFP's actions on
norepinephrine and dopamine.

First, DFP as a drug could,

itself, produce these effects by directly stimulating the
adrenergic neuron, in a yet unknown manner, producing the
elevation of dopamine levels, probably through stimulation of
dopamine synthesis from DOPA, as well as causing the release
of norepinephrine and a subsequent lowering of the levels
of this transmitter.

Further, these direct actions of DFP

should be entirely independent of any mediation by acetylcholine,
whether through DFP stimulation of nearby cholinoceptive
neurons or interneurons, causing the release of acetylcholine
which would be indirectly responsible for the actions of DFP
on both norepinephrine and dopamine levels.

The second

proposed possibility to explain DFP's actions upon norepinephrine
and dopamine levels relates to an indirect action by DFP.
This action would be due to acetylcholine, the levels of which
are elevated by DFP's inhibition of cholinesterases (acetyl-,
butrylcholinesterase, etc; cf. Methods).

Acetylcholine would

then act on the adrenergic neuron or an interneuron, to cause
an elevation in dopamine levels, as well as to cause the release

'

and lowering of the norepinephrine levels.

The third proposed

possibility concerns the inhibition of dopamine-/.3-hydroxylase
by DFP or by the accumulated acetylcholine to produce the
norepinephrine and dopamine responses.
The results of experiments on the effects of DFP on

~
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norepinephrine and dopamine at various intervals following
DFP (cf. Figures 11 and 12), were interpreted as not supporting
the third possibility.

Had

dopamine-~-hydroxylase

been

inhibited by DFP, norepinephrine levels would have continued
to decrease, and in fact Billiet et al.

(1970) found a decrease

in norepinephrine levels in rabbit caudate nucleus following
dopamine-a-hydroxylase inhibition.
observed in the present studies.

No such effects were
Moreover, by three hours

both the norepinephrine and the dopamine levels were
approaching their respective control levels.
Furthermore, there is no supportive evidence for the
first possibility, i.e. the direct action of DFP.

However,

supportive evidence does exist with regard to the second
possibility.

The findings that DFP (2.5 mg/kg) caused

nearly 100 percent inhibition of cholinesterase activity in
the thalamus, the hypothalamus, the midbrain, and the caudate
nucleus, as well as the subsequent elevation in the levels
of acetylcholine levels in these _four brain areas, allow,
at present, the conclusion that the DFP-induced effects
upon both norepinephrine and d()pamine, i.e. the elevation in
dopamine levels and the decrease in norepinephrine levels,
should be due to the elevated acetylcholine levels resulting
from DFP inhibition of cholinesterase.
Consistent with the above proposal is that, cholinoceptive
neurons and high levels of acetylcholine and acetylcholinesterase
were found by many investigators in the midbrain-diencephalon
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area and in the caudate nucleus {for references, cf. Curtis
and Crawford, 1969; Karczmar, 1967, 1969, and 1970, as well
as in the present studies, cf. Tables 3 and 4).

Both dopamine

and norepinephrine are also present in these two areas, dopamine
being particularly high in the latter {Bertler and Rosengren,
1959; cf. also Tables 1 and 2).

These areas are richly inter-

connected, and the direct dopaminergic nigro-striatal pathway
{Anden et al., 1966) is particularly important in the present
context.

Cell bodies of both norepinephrine and dopamine

containing neurons have been shown to originate in the
mesencephalic {midbrain) region and project rostrally in nerve
bundles to the striatum {caudate nucleus and putamen) in the
case of the dopamine containing neurons, and to the diencephalon
{thalamus and hypothalamus) and telencephalon {cortex) in the
case of the norepinephrine containing neurons {Anden et al., 1966).
While many of the pathways in question may be cholinoceptive
{for references, cf. Silver, 1967; Karczmar, 1970), it is not
known whether this is also true for the important nigro-striatal
connection, although recent findings indicate the presence
of acetylcholinesterase in several important nigro-striatal

"

fascicles {Olivier et al., 1970).

The presence of both

cholinoceptive and adrenergic neural pathways in the midbraindiencephalon and nigro-striatal regions is supportive of the
proposal that acetylcholine may induce the observed effects

r
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either by activating the catecholamine neurons of the mesencephalon-diencephalon as well as of the striate area (possibly

via cholinoceptive interneurons, cf. Glisson and Karczmar,
1970), or via the cholinoceptive participation in the pathways
which connect these two areas.

Of course, DFP administered

systemically will cause acetylcholine accumulation outside
of these areas as well, and diffusing or circulating acetylcholine, if it should escape cholinesterase, may cause similar
effects on the monoamines elsewhere in the brain, which then
would not be due to local, synaptic actions.
Interesting additional conceptualizations may be offered
on the basis of the results obtained with the tertiary and
quaternary atropine.

The blocking actions of atropine on the

acetylcholine-induced norepinephrine depletion and dopamine
accumulation were not unexpected, and they supported the
notion of the central site of the acetylcholine action on the
monoamines.

Even without the combined JB835-DOPA pretreatment,

acetylcholine produced an elevation in dopamine levels and
a decrement in norepinephrine levels in rabbits receiving
only JB835, although the augmentation of response was much

'

less than that observed after the addition of DOPA.

Under these

conditions, atropine (4.0 mg/kg) blocked nearly completely the
acetylcholine-induced decrease in norepinephrine.

The fact

that AT.MN was incapable of blocking the norepinephrine depletion
induced by acetylcholine in the case of the mesencephalon-diencephalon further strengthens this conceptulization.

On the

r
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other hand, the conspicuous effectiveness of the quaternary
atropine in blocking the dopamine increase induced by acetylcholine (particularly in the case of the diencephalon-mesencephalon area) seems to suggest that the periphery is involved
also.

Indeed, the effects of acetylcholine are not restricted

to the central nervous system.

The two doses of DFP employed

in this study would produce lethality in at least 50 percent
of the rabbits in a 24 hour period (cf. Karczmar, 1967}, and
they are capable of inducing marked peripheral effects which
in the rabbit are of the muscarinic nature (cf. Holmstedt,
1959).

These effects are readily blocked by the quaternary

atropinics, although the tertiary mother compound may be
expected to antagonize them to an extent also.

It may be

speculated that, in the "loaded" animals the acetylcholineinduced increase in dopamine levels- and in the rate
of its synthesis- may depend ontheir peripheral actions and the
more marked action of ATMN may be due to its particular
effectiveness at the parasympathetic periphery.

Moreover,

atropine at a higher dose (4.0 mg/kg), given to rabbits pretreated with JB835, was able to produce a more marked block of

'

the acetylcholine-induced elevation in dopamine levels than
at the lower (2.0 mg/kg) dose in the JB835-DOPA treated animals;
the block produced by the higher dose of atropine closely
resembled the block of the acetylcholine-induced dopamine
'·· elevation seen with the ·administration of ATMN ( 2. 0 mg/kg},

l
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indicating atropine's peripheral effectiveness in blocking
the acetylcholine-induced elevation in the dopamine levels,
provided doses greater than those of ATMN needed to produce
this block are used.

On the other had, as atropine, but

not the quaternary atropine affected the acetylcholine-induced
changes in norepinephrine in the "loaded" animals, this
particular mechanism may be entirely central in its location.
On the basis of these findings, a working neural model
was constructed to explain the effects of acetylcholine on the
central norepinephrine and dopamine levels (Figure 27).
It is proposed that administration of DFP leads to the
accumulation of acetylcholine within the central and autonomic nervous systems by inhibiting the activity of cholinesterases.

Further inventigations may, in fact, show that

acetylcholinesterase is the cholinesterase particularly involved.
Centrally, acetylcholine, acting either through an interneuron
(labelled (1) in the figure) or directly through cholinoceptive
sites on the adrenergic neuron (labelled (2) in the figure)
causes the release of norepinephrine from the adrenergic
terminals.

In addition, perip(leral effects of acetylcholine,

relayed via the afferent pathways to the adrenergic neuron,
cause the elevation in dopamin:! levels, probably through
stimulation of the synthesis of dopamine from DOPA.

The effect

postulated to depend on the stimulation of,sensory afferents
by the accumulation of acetylcholine, is not, at present, well

r
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FIGURE 27
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+
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+

NORE Pl N EPH RINE

Hypothetical model of central cholinergic involve-

ment in adrenergic nerve transmission.
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understood.

The data indicate that it is sensit!_ve to the

blocking actions of AT.MN and AtSO

(cf. below for further
4

discussion) •
It was apparent that the most prominent effects of acetylcholine upon the norepinephrine and the dopamine levels occurred
in the midbrain-diencephalon.

The additional studies demon-

strated that the acetylcholine-induced elevation in dopamine
levels and decrease in norepinephrine levels was wide-spread,
as it occurred in the midbrain, the thalamus, the hypothalamus,
and also in the non-midbrain-diencephalon area, the hippocampus.

These data were very much in agreement with findings

obtained with regard to the midbrain-diencephalon region.
In addition, it was found that ATMN blocked the elevation
of the dopamine levels within these four brain areas, but was
ineffective in preventing the acetylcholine-induced decrease
in norepinephrine levels.

This suggests that the sensory

afferents, i.e. the lateral spinothalamic tract,· are in close
contact with the adrenergic neurons of the individual areas.
Supportive of this concept is the fact

~hat

sensory afferents

from the lateral spinothalamic tract are reported to distribute

'

through the reticular formation and thalamus from which branching
collaterals arise invading these regions.

Moreover, various

peripheral sensory receptors, i.e. pain, touch, etc., are
reported to be stimulated by acetylcholine (personal communication,
R. Wurster).

Additional evidence of widespread sensory influence
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comes from EEG and evoked potential experiments in which
enviromental stimuli, i.e. sound, pain, light, often trigger
widespread central alerting (Himwich, 1962}.
To expand further upon this point, one might conclude that
the cholinergically mediated peripheral influence upon the
central nervous system reflected in the effect upon dopamine
levels- could well be one of the mechanisms by which behavorial
stresses act to influence central responses.

In ·fact, it is

most probable that the same sensory afferents are involvedin both the acetylcholine- and the stress-induced effects
upon the central nervous system.

The question which remains

to be answered is whether certain types of stressful conditions
produce similar effects, as acetylcholine does, upon the
dopamine levels.
Principal criticism of the studies purporting to show central
drug responses such as these is that the drugs, particularly
DFP, were administered via a peripheral route.

Such routes of

administration allow for stimulation of peripheral sites which
contribute to, or modify, the central effect of the drug.
This type of contribution was observed in these studies with

'

regard to the ATMN sensitive, acetylcholine-induced elevation
in dopamine levels.

By using the quaternary atropinic, AT.MN,

it was attempted to demonstrate those responses to acetylcholine
"Which were central in origin, as AT.MN was reportedly unable
-to pass through the blood brain barrier at the dose used,
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2.0 mg/kg (Albanus, 1970).

However, it was possible that

peripheral sites other than those blocked by AT.MN also
contributed to the central actions of acetylcholine, although
such additional actions of acetylcholine seemed remote.
Nevertheless, demonstration of the central actions of acetylcholine divorced from any peripheral influence was necessary
if contribution to acetylcholine's central actions by nonATMN sensitive sites was to be ruled out.
The results of the intraventricular injection of DFP indicated
that norepinephrine was released by this mechanism and these
results obtained following the intraventricular DFP administration
resembled those due to s.c. DFP.

On the other hand, there

was an absence of any elevation in dopamine levels, contrary
to the response to s.c. administered DFP.

That no dopamine

elevation occurred in these experiments, indicates an extracentral mechanism.

Further, AT.MN given prior to the intra-

ventricular injection of DFP had no effect on dopamine levels,
compared to the ability of AT.MN to block the acetylcholineinduced elevation of dopamine levels when DFP was administered
via the s.c. route.

'

Thus, it would appear that the central effects of acetylcholine on the central monoamine levels could be divorced
from those actions of acetylcholine which are peripherally
mediated.

Moreover, the possibility of acetylcholine stimulating

the ATMN-insensitive peripheral sites, which could contribute
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to the acetylcholine-induced release of norepinephrine, can
be eliminated.

Had the acetylcholine-induced release of

norepinephrine been due to such peripheral stimulation of
AT.MN-insensitive sites, then lowering of the norepinephrine
levels would not have been observed following the intraventricular injection of DFP.

As such, a lowering of the

norepinephrine levels was observed, a central rather than
peripheral mechanism may be suggested for this action of
acetylcholine.
Before drawing final conclusions, mention should be made of
the many other uninvestigated, but not forgotten, mechanisms
which might have been involved.

The possibility of acetyl-

choline actions on enzyme systems such as catechol-0-methyl
transferase and/or DOPA decarboxylase exists.

Similarly,

turnover studies of norepinephrine and dopamine would lend
additional understanding to the observed responses, as would
evoked potential and fluorescence microscopy studies.

The

possibility of other transmitter involvement, i.e. serotonin,
tryptamine, histamine, is very real.

It is impossible to

investigate all possibilities tin a single dissertation, but
hopefully it will inspire additional investigations.

,.
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SUMMARY

In the thalamus, the hypothalamus, the midbrain, and the
caudate nucleus in rabbit brain, DFP (2.5 mg/kg) was found
to cause nearly 100 percent inhibition of cholinesterase
activity.

In addition, pretreatment of the animals with JB835-

DOPA cornpinations had no effect upon cholinesterase activity
in these four brain areas compared to cholinesterase activity
in identical brain areas of control (no drug) animals, indicating
that the monoamines norepinephrine and dopamine, elevated by the
pretreatment, are not active on this enzyme system.
Data was also presented showing that acetylcholine levels
in the thalamus, the hypothalamus, the midbrain, and the
caudate nucleus in rabbit brain were elevated more than 100
percent over appropriate control acetylcholine levels by this
dose of DFP (2.5 mg/kg}.

Of importance was the finding that

elevated norepinephrine and dopamine levels were without
effect upon the acetylcholine levels, indicating that adrenergic
actions upon cholinoceptive nebrons do not exist in these
rabbit brain parts.
Studies were subsequently carried out to demonstrate the
central effects induced by the elevated central levels of
acetylcholine as a result of cholinesterase inhibition by DFP.
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Data were presented which link peripheral administration of
DFP and the subsequent elevation in acetylcholine levels to
a significant decrement of central norepinephrine in the midbraindiencephalon, and·· to some extent in the caudate nucleus.

These

findings are supported by evidence of identical responses
occurring in the midbrain, the thalamus, the hypothalamus,
and the hippocampus due to acetylcholine.
Dopamine levels, unlike norepinephrine levels, were significantly
elevated in the midbrain-diencephalon by acetylcholine and to
a lesser extent in the caudate

~ucleus.

Acetylcholine induced

a similar effect on dopamine levels in the midbrain, the thalamus,
the hypothalamus, and the hippocampus.

Interestingly, however,

acetylcholine's actions on dopamine and on norepinephrine occurred
only following pretreatment with JB835, DOPA, or the JB835 and
DOPA-combination; this suggests that acetylcholine's actions
are best observed under optimal conditions for monoamine storage
and synthesis.

Yet, acetylcholine may induce less pronounced

changes under less favorable conditions as well.
Additional conceptulizations were offered on the basis of
the results obtained· with the tertiary and quaternary atropine.
The blocking actions of atropine on the acetylcholine-induced
norepinephrine depletion and dopamine accumulation were not
unexpected, and they supported the notion of the central site
of action of acetylcholine.

The fact that ATMN was incapable

of blocking the norepinephrine depletion induced by acetylcholine

r
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in the case of the midbrain-diencephalon, further strengthens
this conceptulization.

However, the ability of ATMN to

block the dopamine accumulation induced by acetylcholine
suggested peripheral rather than central involvement for
this action.
DFP (200µg)

injected intraventricularly into rabbits caused

a decrease in norepinephrine levels in the midbrain-diencephalon
which ATMN was unable to block.

Significant accumulation of

dopamine in the midbrain-diencephalon was not, however,_ observed
following intraventricular injections of DFP: nor did AT.MN
produce any significant effects on dopamine levels.
The conclusions arrived at from these studies led to the
postulation of a neural model to explain the elevation in dopamine
levels and the decrease in norepinephrine levels resulting from
the accumulation of acetylcholine, resulting from DFP's inhibition
of cholinesterase activity in rabbit brain.
It is proposed, based upon data obtained in these experiments,
that elevated central acetylcholine levels, resulting from
DFP's inhibition of cholinesterase activity, acts either
through an interneuron or

dir~ctly

through cholinoceptive

sites on the adrenergic neuron to cause the release of
norepinephrine.

In addition, DFP-induced elevation of acetyl-

choline leads through stimulation of the atropine and AT.MN
sensitive sites, to an elevation of the dopamine levels,
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probably through stimulation of the synthesis of dopamine
from DOPA.
Under the experimental conditions employed in these studies,
neurochemical evidence of cholinergic-adrenergic coupling
phenomena was thus demonstrated.

The role of such a mechanism

is, however, unclear.
It is hopeful that these observations will provide a
foundation upon which future investigations of the cholinergicadrenergic linkage will begin.

'
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